var title_f27_20_27968="Wickhams striae on plaque";
var content_f27_20_27968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61523&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the thick, violaceous, hyperkeratotic plaque with a white, lacelike pattern on the surface (Wickham striae).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD, and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27968=[""].join("\n");
var outline_f27_20_27968=null;
var title_f27_20_27969="Pattern of benign calcification";
var content_f27_20_27969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patterns of benign calcification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of different patterns of benign calcification. In clockwise orientation from top left: target, diffuse, popcorn, and lamellated calcification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27969=[""].join("\n");
var outline_f27_20_27969=null;
var title_f27_20_27970="Patient information: Preterm labor (The Basics)";
var content_f27_20_27970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1732\">",
"         Patient information: Having twins (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/52/17218\">",
"         Patient information: Miscarriage (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?38/21/39249\">",
"         Patient information: Preterm premature rupture of membranes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/62/8163\">",
"         Patient information: What to expect in the NICU (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/38/2659\">",
"         Patient information: When a baby is born premature (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/52/35650\">",
"         Patient information: Preterm labor (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Preterm labor (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/preterm-labor-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H196918596\">",
"      <span class=\"h1\">",
"       What is preterm labor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;&ldquo;Preterm labor&rdquo; is labor that starts before 37 weeks of pregnancy (3 or more weeks before the woman&rsquo;s due date). Pregnancy normally lasts about 40 weeks, counting from the first day of the woman&rsquo;s last period. Going into labor before 37 weeks of pregnancy can be dangerous, because babies who are born preterm can have serious health problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196918603\">",
"      <span class=\"h1\">",
"       What causes preterm labor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is often hard to know why a woman has preterm labor.",
"     </p>",
"     <p>",
"      Some things that may cause preterm labor are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleeding or other problems in the uterus",
"       </li>",
"       <li>",
"        Being pregnant with twins, triplets, or more babies",
"       </li>",
"       <li>",
"        Infection in the uterus or other part of the body",
"       </li>",
"       <li>",
"        Stress",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196918610\">",
"      <span class=\"h1\">",
"       Who is at risk for preterm labor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is usually not possible to tell who will go into labor early. Black women are more likely to give birth early than white, Latino, or Asian women.",
"     </p>",
"     <p>",
"      Women at highest risk of preterm birth (having a baby 3 or more weeks before the due date) are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Women who had a preterm birth in the past",
"       </li>",
"       <li>",
"        Women who are pregnant with more than one baby (twins, triplets, etc.)",
"       </li>",
"       <li>",
"        Women with certain problems of the uterus or cervix (the bottom part of the uterus that leads to the vagina)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other problems that might increase the risk of preterm birth are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Using illegal drugs, such as cocaine",
"       </li>",
"       <li>",
"        Smoking",
"       </li>",
"       <li>",
"        Certain infections (including kidney infections and the flu)",
"       </li>",
"       <li>",
"        Poor diet and being underweight",
"       </li>",
"       <li>",
"        Vaginal bleeding during the pregnancy",
"       </li>",
"       <li>",
"        Surgery in the belly area during pregnancy",
"       </li>",
"       <li>",
"        Some health problems",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196918617\">",
"      <span class=\"h1\">",
"       What are the symptoms of preterm labor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of preterm labor are the same as with normal labor:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tightening of the uterus, also called &ldquo;contractions.&rdquo; These can make the belly feel hard while they are happening. They eventually become painful.",
"       </li>",
"       <li>",
"        A change in the fluid that comes out of the vagina (it might be watery, thick, or bloody)",
"       </li>",
"       <li>",
"        Pain or pressure low in the belly or in thighs",
"       </li>",
"       <li>",
"        Pain in the low back",
"       </li>",
"       <li>",
"        Belly cramps, sometimes with diarrhea",
"       </li>",
"       <li>",
"        &ldquo;Broken water,&rdquo; which feels like a trickle or gush of fluid from the vagina",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some women have &ldquo;Braxton Hicks contractions.&rdquo; These are contractions that happen several minutes apart. They are usually not too painful and don&rsquo;t get stronger or more frequent over time. They often go away when you lie down or rest. Braxton Hicks contractions are sometimes called &ldquo;false labor contractions.&rdquo; That&rsquo;s because they don&rsquo;t really mean that you are going into labor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196918624\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you think you might be in labor, call your doctor, nurse, or midwife. You should also call if you have blood or fluid leaking from your vagina, or if you have more than 6 contractions in 1 hour. (That means that contractions are 10 minutes apart.) It is hard to know if you are actually in labor without being seen by a doctor or nurse.",
"     </p>",
"     <p>",
"      Your doctor or nurse will be able to tell if you are in labor by looking at your cervix and checking to see how often your contractions are happening. There are also tests your doctor or nurse can do to find out what is going on. It might take an hour or two to figure out whether you are in preterm labor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196918631\">",
"      <span class=\"h1\">",
"       Does preterm labor mean that my baby will be born early?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not always. Some women who have preterm labor end up having their baby at the normal time.",
"     </p>",
"     <p>",
"      Sometimes, the doctor or nurse will decide that it is better for the baby to be born early than to try to stop the labor. What is right for you will depend on your individual situation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196918638\">",
"      <span class=\"h1\">",
"       How is preterm labor treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are different treatments for preterm labor. The right treatment for you will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What is causing your labor",
"       </li>",
"       <li>",
"        How far along you are in your pregnancy",
"       </li>",
"       <li>",
"        How healthy you and your baby are",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Your doctor might give you medicine to try to stop or slow down your labor. These medicines are called &ldquo;tocolytic agents.&rdquo; If you are less than 34 weeks pregnant, your doctor might also give you medicines called steroids. These medicines will speed up the growth of your baby&rsquo;s lungs. This will help the baby to breathe if he or she is born early. (The steroids used here are not the same as the steroids that athletes take to build muscle.)",
"     </p>",
"     <p>",
"      Medicines used to stop preterm labor do not always work. If you do end up giving birth early, your healthcare team can take steps to protect the health of the baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196918645\">",
"      <span class=\"h1\">",
"       Can preterm labor be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no way to prevent preterm labor most of the time. If you had a preterm birth before, your doctor might give you a hormone (progesterone) to decrease the chance of it happening again. It is important to pay attention to how you are feeling during pregnancy. Call your doctor or nurse right away if you think you might be in labor.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H196918652\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/21/39249?source=see_link\">",
"       Patient information: Preterm premature rupture of membranes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=see_link\">",
"       Patient information: Miscarriage (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=see_link\">",
"       Patient information: What to expect in the NICU (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/38/2659?source=see_link\">",
"       Patient information: When a baby is born premature (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=see_link\">",
"       Patient information: Having twins (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"       Patient information: Preterm labor (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/20/27970?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15609 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-813CF6A707-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27970=[""].join("\n");
var outline_f27_20_27970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196918596\">",
"      What is preterm labor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196918603\">",
"      What causes preterm labor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196918610\">",
"      Who is at risk for preterm labor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196918617\">",
"      What are the symptoms of preterm labor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196918624\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196918631\">",
"      Does preterm labor mean that my baby will be born early?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196918638\">",
"      How is preterm labor treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196918645\">",
"      Can preterm labor be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196918652\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/44/1732?source=related_link\">",
"      Patient information: Having twins (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17218?source=related_link\">",
"      Patient information: Miscarriage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=related_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/21/39249?source=related_link\">",
"      Patient information: Preterm premature rupture of membranes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8163?source=related_link\">",
"      Patient information: What to expect in the NICU (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/38/2659?source=related_link\">",
"      Patient information: When a baby is born premature (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_20_27971="Ciprofloxacin (otic): Drug information";
var content_f27_20_27971=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin (otic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/21/15700?source=see_link\">",
"    see \"Ciprofloxacin (otic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/48/38658?source=see_link\">",
"    see \"Ciprofloxacin (otic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9611245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cetraxal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9660666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Otic;",
"     </li>",
"     <li>",
"      Antibiotic, Quinolone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9611438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;display:inline\">",
"     <b>",
"      Acute otitis externa:",
"     </b>",
"     Otic solution: Instill 0.25 mL (contents of 1 single-dose container) into affected ear twice daily for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9611437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/48/38658?source=see_link\">",
"      see \"Ciprofloxacin (otic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Acute otitis externa:",
"     </b>",
"     Otic solution: Children &ge;1 year: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9611439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9611531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, otic, as hydrochloride [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cetraxal&reg;: 0.5 mg/0.25 mL (14s) [equivalent to ciprofloxacin base 0.2%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9611248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9611470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     For otic use only. Prior to use, warm solution by holding container in hands for at least 1 minute. Patient should lie down with affected ear upward and medication instilled. Patients should remain in the position for at least 1 minute to allow penetration of solution.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9611273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of acute otitis externa due to susceptible strains of",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     or",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9611552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cetraxal&reg; may be confused with cefTRIAXone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ciprofloxacin may be confused with cephalexin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9612499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Application site pain (2% to 3%), fungal superinfection (2% to 3%), pruritus (2% to 3%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9611319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciprofloxacin, any component of the formulation, or other quinolones",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9611320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe hypersensitivity reactions have occurred with quinolone therapy. Prompt discontinuation of drug should occur if skin rash or other symptoms of hypersensitivity arise.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection. If superinfection occurs, discontinue use and institute appropriate alternative therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tendon inflammation/rupture: There have been reports of tendon inflammation and/or rupture with systemic quinolone antibiotics. Exposure following otic administration is substantially lower than with systemic therapy. Discontinue at first sign of tendon inflammation or pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For otic use only. If infection is not improved after 1 week, consider culture to identify organism.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9611341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9611276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9779657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal studies; therefore, the manufacturer classifies ciprofloxacin otic as pregnancy category C. When administered orally or I.V., ciprofloxacin crosses the placenta. Refer to the Ciprofloxacin (Systemic) monograph for details. The amount of ciprofloxacin available systemically following topical application of the otic drops is expected to be significantly less in comparison to oral or I.V. doses.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9611280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9779660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally or I.V., ciprofloxacin enters breast milk. Refer to the Ciprofloxacin (Systemic) monograph for details. The amount of ciprofloxacin available systemically following topical application of the otic drops is expected to be significantly less in comparison to oral or I.V. doses; however, breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cetraxal Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (1): $10.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ciprofloxacin HCl Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2% (1): $7.51",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14721646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AC Ear Drops (IN);",
"     </li>",
"     <li>",
"      Adiflox (IN);",
"     </li>",
"     <li>",
"      Ceflox (IN);",
"     </li>",
"     <li>",
"      Ciloxan (AU);",
"     </li>",
"     <li>",
"      Ciprodar (HK);",
"     </li>",
"     <li>",
"      Otosec (CO, PE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9611382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits DNA-gyrase in susceptible organisms; inhibits relaxation of supercoiled DNA and promotes breakage of double-stranded DNA",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/20/27971/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9050 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27971=[""].join("\n");
var outline_f27_20_27971=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611245\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9660666\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611438\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611437\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611439\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611531\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611248\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611470\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611273\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611552\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612499\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611319\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611320\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299046\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611341\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611276\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9779657\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611280\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9779660\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322775\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14721646\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9611382\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9050\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9050|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/7/26740?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/39/36468?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/50/6947?source=related_link\">",
"      Ciprofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/21/15700?source=related_link\">",
"      Ciprofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/48/38658?source=related_link\">",
"      Ciprofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/5/20570?source=related_link\">",
"      Ciprofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/11/17590?source=related_link\">",
"      Ciprofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/11/44216?source=related_link\">",
"      Ciprofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_20_27972="Neointimal hyperplasia";
var content_f27_20_27972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neointimal hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This represents a longitudinal section taken through the venous anastomosis of a PTFE graft. The graft material is recognizable as a black felt-like layer (labeled PTFE). The lumen of the graft would be at the right lower corner. The intima should be a relatively thin layer, thinner than the graft material seen here.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gerald Beathard, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27972=[""].join("\n");
var outline_f27_20_27972=null;
var title_f27_20_27973="Exercise-induced hematuria";
var content_f27_20_27973=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Exercise-induced hematuria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27973/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27973/contributors\">",
"     Angelo Mercieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27973/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27973/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27973/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27973/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/20/27973/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is the one of the many causes of hematuria (increased red blood cells excretion in the urine) (",
"    <a class=\"graphic graphic_figure graphicRef61296 \" href=\"UTD.htm?13/34/13870\">",
"     figure 1",
"    </a>",
"    ). Exercise-induced hematuria can be defined as gross or microscopic hematuria that occurs after strenuous exercise and resolves with rest in individuals with no apparent underlying kidney or urinary tract pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to exercise-induced hematuria in otherwise healthy individuals will be reviewed here. Exercise may also worsen hematuria in patients with underlying glomerular disease, such as IgA nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general evaluation of adults or children with hematuria is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=see_link\">",
"     \"Evaluation of microscopic hematuria in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1127?source=see_link\">",
"     \"Evaluation of gross hematuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematuria has been described after a variety of forms of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. These include contact sports, such as football and boxing, and noncontact sports, such as long-distance (marathon or endurance) running [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/6-8\">",
"     6-8",
"    </a>",
"    ], rowing, and swimming. Hematuria appears to be rare with cycling but has been described, even with stationary bike riding (eg, spinning) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency with which hematuria occurs with long-distance running was evaluated in a study of 45 male and female participants who competed in an ultra long-distance marathon [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/6\">",
"     6",
"    </a>",
"    ]. After the race, 11 (24 percent) had hematuria. The hematuria disappeared within seven days. A similar incidence (18 percent) was noted in a report of 50 marathon runners who did not have hematuria on prerace samples obtained daily for three days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of increased red cell excretion after long-distance running is higher when defined by more sensitive testing. This was illustrated in a report of 48 participants in a long-distance race [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/8\">",
"     8",
"    </a>",
"    ]. The urinary red cell count increased in 44 and to values above the normal range",
"    <span class=\"nowrap\">",
"     (8000/mL",
"    </span>",
"    in centrifuged urine) in 33 (69 percent). These changes would not usually be detectable in routine practice, since only five tested positive for blood on the urine dipstick.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Traumatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct trauma to the kidneys",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bladder may be responsible for the hematuria associated with contact sports such as football and boxing. In addition, trauma to the bladder may occur with long-distance running and rarely with cycling due to the up and down movement of the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/6,7,9\">",
"     6,7,9",
"    </a>",
"    ]. Ecchymoses and frank contusions have been noted on cystoscopy after long-distance running, possibly due to repeated impact of the flaccid wall of the bladder against the bladder base [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. A possible exacerbating factor is a near empty bladder, which increases the likelihood of apposition of the surfaces of the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/7\">",
"     7",
"    </a>",
"    ]. Bicycling-related hematuria is attributed to the vigorous and repeated collisions of the perineum with the saddle during acrobatic or bumpy rides (bicycle-seat hematuria) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/12\">",
"     12",
"    </a>",
"    ]. Urinary symptoms associated with bicycle riding exist also in female bicyclists [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/13\">",
"     13",
"    </a>",
"    ]. Among 282 female members of a bicycling club, one third experienced perineal trauma, 19 percent of which were associated with hematuria and dysuria, and 34 percent with perineal numbness. The frequency and the severity of symptoms were related to bicycling exposure as measured in cycling hours and miles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/13\">",
"     13",
"    </a>",
"    ]. In some cases of cycling-related hematuria, stopping cycling or adjusting the saddle position prevented recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The study of 48 participants in a long-distance race cited above used phase contrast microscopy, which is more sensitive than standard microscopy. This study found dysmorphic red cells in all runners, red cell casts in 10, and new proteinuria in 18, all of which are indicative of glomerular bleeding (",
"    <a class=\"graphic graphic_picture graphicRef55778 graphicRef79440 graphicRef62064 \" href=\"UTD.htm?8/10/8359\">",
"     picture 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/8\">",
"     8",
"    </a>",
"    ], which also appears to account for the small number of red cells in normal urine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/16\">",
"     16",
"    </a>",
"    ]. Most [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/17\">",
"     17",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/6\">",
"     6",
"    </a>",
"    ] other studies have also found dysmorphic red cells with exercise-induced hematuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link&amp;anchor=H1824471562#H1824471562\">",
"     \"Etiology and evaluation of hematuria in adults\", section on 'Red cell morphology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nontraumatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematuria can occur with participation in noncontact sports such as rowing, swimming, and stationary bike riding (eg, spinning) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/1,4,5,10\">",
"     1,4,5,10",
"    </a>",
"    ]. Several mechanisms have been proposed in these cases but none has been proved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/1\">",
"     1",
"    </a>",
"    ]. One such mechanism is renal ischemia due to shunting of blood to exercising muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Another proposed mechanism is that lactic acidosis resulting from anaerobic conditions increases glomerular permeability, which allows the passage of erythrocytes into the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential cause of nontraumatic exercise-induced hematuria is nutcracker syndrome, which refers to compression of the left renal vein between the aorta and proximal superior mesenteric artery. Nutcracker syndrome can cause both microscopic and gross hematuria, primarily in children and primarily in Asia but also in adults. The hematuria is usually asymptomatic but may be associated with left flank pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=see_link\">",
"     \"Evaluation of microscopic hematuria in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1127?source=see_link\">",
"     \"Evaluation of gross hematuria in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited data suggest an association between hematuria (with or without left flank pain) and exercise in selected adults with nutcracker syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The diagnosis is established by Doppler ultrasonographic assessment of left renal vein diameter and peak velocity or by magnetic resonance angiography or renal venography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ]. Possible therapies in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the mechanism, exercise-induced hematuria appears to be a benign condition with no known long-term morbidity. However, exercise-induced hematuria should be considered a diagnosis of exclusion. In addition to the temporal relation of onset following exercise, the hematuria should remit spontaneously within several days to one week [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. If so, further diagnostic testing is not necessary in most patients.",
"   </p>",
"   <p>",
"    Evaluation for other causes of hematuria is warranted if the hematuria persists well beyond one week of no exercise and may be warranted even with transient hematuria in patients (particularly men) over age 50 (especially if recurrent) and selected other patients at increased risk for bladder or kidney cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Etiology and risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\", section on 'Established risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that evaluation for underlying disease is warranted if the hematuria following exercise is not dysmorphic (ie, nonglomerular) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/8\">",
"     8",
"    </a>",
"    ]. However, this recommendation only applies when the examiner has experience in identifying dysmorphic red cells and preferably has access to phase contrast microscopy.",
"   </p>",
"   <p>",
"    Exercise-induced gross hematuria should be differentiated from two other potential causes of red to brown urine following exercise: myoglobinuria due to rhabdomyolysis; and march hemoglobinuria, probably resulting from trauma to red cells as they move through the blood vessels on the dorsal aspects of the feet [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/5,24\">",
"     5,24",
"    </a>",
"    ]. Exercise-induced hemolysis may also be seen in patients with alterations in erythrocyte membrane spectrins; it primarily occurs in the early phase of an ultraendurance race due to a relative older cell population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27973/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H22#H22\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Mechanical trauma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=see_link&amp;anchor=H31734801#H31734801\">",
"     \"Causes of rhabdomyolysis\", section on 'Nontraumatic exertional rhabdomyolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With myoglobinuria or hemoglobinuria, the urine dipstick is positive for heme in the urine supernatant, but hematuria is not seen on microscopic examination of the urine unless there is concurrent hematuria. The approach to patients with red to brown urine is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link&amp;anchor=H4#H4\">",
"     \"Urinalysis in the diagnosis of kidney disease\", section on 'Red to brown urine'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/51/17202?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=see_link\">",
"       \"Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=see_link\">",
"       \"Patient information: Glomerular disease overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H138038\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise-induced hematuria can be defined as gross or microscopic hematuria (increased red cell excretion in the urine) that occurs after strenuous exercise and resolves with rest in individuals with no apparent underlying kidney or urinary tract pathology. It is a benign condition with no known long-term morbidity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Direct trauma to the kidneys",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bladder may be responsible for hematuria associated with contact sports such as football and boxing. Trauma to the bladder may also occur with long-distance running and cycling. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Traumatic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematuria that occurs in association with noncontact sports may be explained by nontraumatic mechanisms including renal ischemia due to shunting of blood to exercising muscles and the nutcracker syndrome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Nontraumatic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation is not warranted in patients under age fifty who are not at increased risk for bladder or kidney cancer, providing there is a temporal association of hematuria with exercise and spontaneous remission occurs within several days to one week following cessation of exercise. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation for other causes is warranted if the hematuria persists beyond one week of no exercise and may be warranted even with transient hematuria in patients (particularly men) over age 50 and selected other patients at increased risk for bladder or kidney cancer. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/1\">",
"      Jones GR, Newhouse I. Sport-related hematuria: a review. Clin J Sport Med 1997; 7:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/2\">",
"      Colasanti G, Banfi G, di Belgiojoso GB, et al. Idiopathic IgA mesangial nephropathy: clinical features. Contrib Nephrol 1984; 40:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/3\">",
"      Tomino Y, Sakai H. Exacerbating factors in patients with IgA nephropathy. Semin Nephrol 1987; 7:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/4\">",
"      Gambrell RC, Blount BW. Exercised-induced hematuria. Am Fam Physician 1996; 53:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/5\">",
"      Abarbanel J, Benet AE, Lask D, Kimche D. Sports hematuria. J Urol 1990; 143:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/6\">",
"      Kallmeyer JC, Miller NM. Urinary changes in ultra long-distance marathon runners. Nephron 1993; 64:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/7\">",
"      Blacklock NJ. Bladder trauma in the long-distance runner: \"10,000 metres haematuria\". Br J Urol 1977; 49:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/8\">",
"      Fassett RG, Owen JE, Fairley J, et al. Urinary red-cell morphology during exercise. Br Med J (Clin Res Ed) 1982; 285:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/9\">",
"      Albersen M, Mortelmans LJ, Baert JA. Mountainbiker's hematuria: a case report. Eur J Emerg Med 2006; 13:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/10\">",
"      Algazy KM. Spinner's hematuria. N Engl J Med 2002; 346:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/11\">",
"      Siegel AJ, Hennekens CH, Solomon HS, Van Boeckel B. Exercise-related hematuria. Findings in a group of marathon runners. JAMA 1979; 241:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/12\">",
"      Leibovitch I, Mor Y. The vicious cycling: bicycling related urogenital disorders. Eur Urol 2005; 47:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/13\">",
"      LaSalle, M, Salimpour, P, Adelstein, M, et al. Sexual and urinary tract dysfunction in female bicyclists. J Urol 1999; 161:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/14\">",
"      Nichols TW Jr. Bicycle-seat hematuria. N Engl J Med 1984; 311:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/15\">",
"      Salcedo JR. Huffy-bike hematuria. N Engl J Med 1986; 315:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/16\">",
"      Fairley KF, Birch DF. Hematuria: a simple method for identifying glomerular bleeding. Kidney Int 1982; 21:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/17\">",
"      Kincaid-Smith P. Haematuria and exercise-related haematuria. Br Med J (Clin Res Ed) 1982; 285:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/18\">",
"      Bellinghieri G, Savica V, Santoro D. Renal alterations during exercise. J Ren Nutr 2008; 18:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/19\">",
"      Mercieri A, Mercieri M, Armanini M, Raiteri M. Exertional haematuria. Lancet 2002; 359:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/20\">",
"      Hanna HE, Santella RN, Zawada ET Jr, Masterson TE. Nutcracker syndrome: an underdiagnosed cause for hematuria? S D J Med 1997; 50:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/21\">",
"      Zhang H, Li M, Jin W, et al. The left renal entrapment syndrome: diagnosis and treatment. Ann Vasc Surg 2007; 21:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/22\">",
"      Shokeir AA, el-Diasty TA, Ghoneim MA. The nutcracker syndrome: new methods of diagnosis and treatment. Br J Urol 1994; 74:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/23\">",
"      Mueller EJ, Thompson IM. Bladder carcinoma presenting as exercise-induced hematuria. Postgrad Med 1988; 84:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/24\">",
"      Oosterom DL, Betjes MG. [Exertion-related abnormalities in the urine]. Ned Tijdschr Geneeskd 2006; 150:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27973/abstract/25\">",
"      Yusof A, Leithauser RM, Roth HJ, et al. Exercise-induced hemolysis is caused by protein modification and most evident during the early phase of an ultraendurance race. J Appl Physiol 2007; 102:582.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3109 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-4327E6E395-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27973=[""].join("\n");
var outline_f27_20_27973=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H138038\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Traumatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nontraumatic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H138038\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3109\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3109|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/34/13870\" title=\"figure 1\">",
"      Causes of hematuria by age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3109|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35424\" title=\"picture 1A\">",
"      Photomicrograph of urine sediment with a red cell cast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/0/24591\" title=\"picture 1B\">",
"      Phase contrast micrograph showing dysmorphic red cells in urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14079\" title=\"picture 1C\">",
"      Scanning electron micrograph showing dysmorphic red cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10777?source=related_link\">",
"      Causes of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1127?source=related_link\">",
"      Evaluation of gross hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/55/30584?source=related_link\">",
"      Evaluation of microscopic hematuria in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/59/23474?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/51/17202?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=related_link\">",
"      Patient information: Glomerular disease overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_20_27974="ECG - Myocarditis";
var content_f27_20_27974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 606px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram in a 17-year-old female with myocarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 586px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram demonstrating decreased QRS voltage with ST segment and T wave abnormalities in a 17-year-old female with myocarditis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27974=[""].join("\n");
var outline_f27_20_27974=null;
var title_f27_20_27975="Tapentadol: Drug information";
var content_f27_20_27975=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tapentadol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/13/40149?source=see_link\">",
"    see \"Tapentadol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13210109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7878273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nucynta&reg;;",
"     </li>",
"     <li>",
"      Nucynta&reg; ER",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12785498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nucynta&reg; IR;",
"     </li>",
"     <li>",
"      Nucynta&trade; CR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7083927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Opioid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7878389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose and dosage intervals should be individualized according to pain severity with respect to patient&rsquo;s previous experience with similar opioid analgesics. To reduce the risk of withdrawal symptoms, it is recommended to taper the dose when discontinuing therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute moderate-severe pain:",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release:",
"     </i>",
"     Day 1: 50-100 mg every 4-6 hours as needed; may administer a second dose &ge;1 hour after the initial dose (maximum dose on first day: 700 mg daily); Day 2 and subsequent dosing: 50-100 mg every 4-6 hours as needed (maximum: 600 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic moderate-severe pain (U.S. and Canadian labeling), neuropathic pain associated with diabetic peripheral neuropathy (U.S. labeling):",
"     </b>",
"     Oral:",
"     <i>",
"      Extended release:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Opioid naive: Initial: 50 mg twice daily (recommended interval: every 12 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Opioid experienced: No adequate data on converting patients from other opioids to tapentadol extended release. In general, begin with a dose that is 50% of the estimated daily tapentadol requirement and use immediate release rescue medications to supplement dose. Per the Canadian product labeling, comparable pain relief was observed between tapentadol CR and oxycodone CR at a dose ratio of 5:1 in clinical studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Conversion from Nucynta&reg; immediate release to extended release: Convert using same total daily dose but divide into 2 equal doses and administer twice daily (recommended interval: ~12 hours) (maximum dose: 500 mg daily).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose titration: Titrate in increments of 50 mg no more frequently than twice daily every 3 days to effective dose (therapeutic range: 100-250 mg twice daily) (maximum dose: 500 mg daily)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7878390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initial: Consider initiating at lower range of dosing. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7878324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-moderate renal impairment: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe renal impairment: Not recommended (not studied); use is contraindicated in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7878325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild hepatic impairment: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate hepatic impairment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Immediate release: Initial: 50 mg every 8 hours or longer (maximum: 3 doses/24 hours). Further treatment for maintenance of analgesia may be achieved by either shortening or lengthening the dosing interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extended release: Initial: 50 mg every 24 hours or longer; maximum: 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment: Not recommended (not studied); use is contraindicated in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7878394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nucynta&reg;: 50 mg, 75 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nucynta&reg; ER: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F12809985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nucynta&trade; CR: 50 mg, 100 mg, 150 mg, 200 mg, 250 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7083931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16327977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Nucynta&reg; Oral Solution: FDA approved October 2012; anticipated availability currently unknown.  Refer to prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F7878271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Nucynta&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176364.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176364.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Nucynta&reg; ER:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM270268.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM270268.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7878392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer orally with or without food. Long acting formulations must be swallowed whole and should",
"     <b>",
"      not",
"     </b>",
"     be split, crushed, broken, chewed, or dissolved; patients should be instructed to swallow 1 tablet at a time, immediately after placing in mouth. Per the Canadian product labeling, immediate release tablets should also be swallowed whole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7083929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release formulation: Relief of moderate-to-severe acute pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Long acting formulation: Relief of moderate-to-severe chronic pain or neuropathic pain associated with diabetic peripheral neuropathy (DPN) when continuous, around-the-clock analgesia is necessary for an extended period of time",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7083925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tapentadol may be confused with traMADol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7878285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Immediate release:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (24%), somnolence (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (30%), vomiting (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (3%), insomnia (2%), anxiety (1%), confusion (1%), dreams abnormal (1%), lethargy (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (3% to 5%), hyperhidrosis (3%), rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hot flushes (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (8%), xerostomia (4%), appetite decreased (2%), dyspepsia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (1%), tremor (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (1%), upper respiratory tract infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Extended release:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Central nervous system: Dizziness (17% to 18%), headache (10% to 15%), somnolence (12% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gastrointestinal: Nausea (21% to 27%), constipation (13% to 17%), vomiting (8% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cardiovascular: Hypotension (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Central nervous system: Fatigue (9%), anxiety (2% to 5%), insomnia (4%), irritability (2%), lethargy (2%), abnormal dreams (1% to 2%), vertigo (1% to 2%), attention disturbances (1%), chills (1%), depression/depressed mood (1%), hypoesthesia (1%), nervousness (1%), sedation (1%), withdrawal syndrome (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dermatologic: Pruritus (1% to 8%), hyperhidrosis (3% to 5%), rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Endocrine &amp; metabolic: Hot flushes (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Gastrointestinal: Diarrhea (7%), xerostomia (7%), appetite decreased (2% to 6%), dyspepsia (1% to 3%), abdominal discomfort (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Genitourinary: Erectile dysfunction (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Neuromuscular &amp; skeletal: Tremor (1% to 3%), weakness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Ocular: Vision blurred (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Respiratory: Dyspnea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Immediate and/or extended release:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, abnormal thinking, agitation, angioedema, ataxia, blood pressure decreased, consciousness depressed, coordination abnormal, disorientation, drug withdrawal, drunk feeling, dysarthria, euphoria, gastric emptying impaired, hallucination, hypersensitivity, memory impaired,  paresthesia, pollakiuria, presyncope, respiratory depression, seizure, syncope, urinary hesitation, urticaria, visual disturbance",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7878279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tapentadol or any component of the formulation; significant respiratory depression; acute or severe asthma or hypercapnia in unmonitored settings or in absence of resuscitative equipment or ventilatory support; known or suspected paralytic ileus; use with or within 14 days of MAO inhibitors",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to opioids; acute respiratory depression, cor pulmonale; gastrointestinal obstruction or any disease/condition that affects bowel transit (eg, ileus of any type, strictures); severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); severe hepatic impairment (Child-Pugh class C); mild, intermittent, or short-duration pain that can be managed with alternative pain medication; management of perioperative pain (controlled release tablets); acute alcoholism, delirium tremens, and seizure disorders; severe CNS depression, increased cerebrospinal or intracranial pressure or head injury; pregnancy; breast-feeding; use during labor/delivery",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7878280\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypotension: Extended release tablets may cause severe hypotension; use with caution in patients with risk factors (eg. hypovolemia, concomitant use of other hypotensive agents). Avoid use in patients with circulatory shock.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Respiratory depression:",
"     <b>",
"      [U.S. Boxed Warning]: Respiratory depression, possibly fatal, may occur. Proper dosing, titration, and monitoring are essential. Extended release tablets must be swallowed whole and should NOT be split, crushed, broken, chewed, or dissolved in order to avoid rapid release and potential for fatal dose.",
"     </b>",
"     Risk for respiratory depression is greatest during the initiation of therapy or with dose increases. Use is contraindicated in patients with significant respiratory depression or conditions that may increase that risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Abdominal conditions: Opioids may obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison&rsquo;s disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Biliary tract impairment: Use caution in patients with biliary tract dysfunction or acute pancreatitis; opioids may cause spasm of the sphincter of Oddi.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure (ICP); exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Serum concentrations are increased in hepatic impairment; use with caution in patients with moderate hepatic impairment (dosage adjustment required). Not recommended for use in severe hepatic impairment (not studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypothyroidism: Use with caution in patients with hypothyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with mild-to-moderate renal impairment; no dosage adjustments recommended. Not recommended for use in severe renal impairment (not studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease or respiratory compromise (eg, asthma, chronic obstructive pulmonary disease [COPD], cor pulmonale, sleep apnea, severe obesity, kyphoscoliosis, hypoxia, hypercapnia); critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizures: Use caution in patients with a history of seizures or conditions predisposing patients to seizures; patients with a history of seizures were excluded in clinical trials of tapentadol. Tramadol, an analgesic with similar pharmacologic properties to tapentadol, has been associated with seizures, particularly in patients with predisposing factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ethanol use: Extended release tablets:",
"     <b>",
"      [U.S. Boxed Warning]: Use of alcohol may increase tapentadol systemic exposure which may lead to possible fatal overdose.",
"     </b>",
"     Avoid alcohol or alcohol-containing medications during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Serotonin syndrome (SS): SS may occur when used in combination with serotonergic agents. Signs of SS may include agitation, tachycardia, hyperthermia, nausea, and vomiting. Avoid use with serotonergic agents such as TCAs, triptans, venlafaxine, trazodone, lithium, sibutramine, meperidine, dextromethorphan, St John's wort, SNRIs, and SSRIs. Use is contraindicated with or within 14 days of MAO inhibitor therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Debilitated patients: Use with caution in debilitated or cachectic patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use opioids with caution in the elderly; consider decreasing initial dose. May have a greater potential for critical respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate patient selection: Extended release tablets:",
"     <b>",
"      Not",
"     </b>",
"     intended for use as an as-needed analgesic;",
"     <b>",
"      not",
"     </b>",
"     intended for the management of acute or postoperative pain; approved for the treatment of chronic pain only (not an as-needed basis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Extended release tablets:",
"     <b>",
"      [U.S. Boxed Warning]: Accidental exposure, especially in children, may lead to fatal overdose.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Abuse/misuse/diversion: Extended release tablets:",
"     <b>",
"      [U.S. Boxed Warning]: Healthcare provider should be alert to problems of abuse, misuse, and diversion.  Potential for abuse may be increased in patients with a history of or family history of substance abuse or mental illness.",
"     </b>",
"     Use with caution in patients with a history of drug abuse or acute alcoholism. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Prolonged use increases risk of abuse, addiction, and withdrawal symptoms. An opioid-containing regimen should be tailored to each patient&rsquo;s needs with respect to degree of tolerance for opioids (na&iuml;ve versus chronic user), age, weight, and medical condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Rescue medication (Canadian labeling recommendations; not in U.S. labeling): During dosage adjustments, immediate release tramadol may be used as rescue medication (maximum dose: 400 mg/day); fentanyl should not be used as rescue medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Withdrawal: Abrupt discontinuation may lead to withdrawal symptoms. Symptoms may be decreased by tapering prior to discontinuation. Mixed agonist/antagonist opioids may diminish the analgesic effect of tapentadol or precipitate withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7878927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Tapentadol. Alcohol (Ethyl) may increase the serum concentration of Tapentadol. Specifically, alcohol may increase the maximum serum concentrations when used with extended-release tapentadol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiemetics (5HT3 Antagonists): May diminish the analgesic effect of Tapentadol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: Tapentadol may enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7878303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects. Bioavailability of extended release tablets may be increased by alcohol; combined use should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: When administered after a high fat/calorie meal, the AUC and C",
"     <sub>",
"      max",
"     </sub>",
"     increased by 25% and 16%, respectively; may administer without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may increase CNS depression and risk of serotonin syndrome).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7878274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7878275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. Not recommended for use during labor and delivery. Use of opioids during pregnancy may produce physical dependence in the neonate. Symptoms of opioid withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, respiratory rate increased, sneezing, tremors, vomiting, or yawning; respiratory depression may occur in the newborn if opioids are used prior to delivery. Use in pregnant women is contraindicated in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7878277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7878278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limited information available on the excretion of tapentadol in human milk; however, data suggests it may be excreted in human milk. The possibility of sedation or respiratory depression in the nursing infant should be considered. Use while breast-feeding is contraindicated in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7878391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Nucynta ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $183.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $339.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (60): $436.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (60): $556.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (60): $556.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Nucynta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $267.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $313.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $416.81",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15040860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status, blood pressure, heart rate; signs of misuse, abuse, or addiction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Extended release tablets: Monitor for respiratory depression for 72 hours of initiating dose.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dol-Proxyvon (IN);",
"     </li>",
"     <li>",
"      Palexia (BG, CH, CZ, DK, EE, FI, GB, IE);",
"     </li>",
"     <li>",
"      Palexia Depot (DK, FI, SE);",
"     </li>",
"     <li>",
"      Palexia IR (AU);",
"     </li>",
"     <li>",
"      Palexia Retard (BG, DE, EE);",
"     </li>",
"     <li>",
"      Palexia SR (GB, IE, SG);",
"     </li>",
"     <li>",
"      Tapcynta (IN);",
"     </li>",
"     <li>",
"      Vorth-TP (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7878306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to &mu;-opiate receptors in the CNS causing inhibition of ascending pain pathways, altering the perception of and response to pain; also inhibits the reuptake of norepinephrine, which also modifies the ascending pain pathway",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7878308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : I.V.: 442-638 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensive metabolism, including first pass metabolism; metabolized primarily via phase 2 glucuronidation to glucuronides (major metabolite: tapentadol-O-glucuronide); minimal phase 1 oxidative metabolism; also metabolized to a lesser degree by CYP2C9, CYP2C19, and CYP2D6; all metabolites pharmacologically inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~32%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Immediate release: ~4 hours; Long acting formulations: ~5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Immediate release: 1.25 hours; Long acting formulations: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (99%: 70% conjugated metabolites; 3% unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Buynak R, Shapiro DY, Okamoto A, et al, \"Efficacy and Safety of Tapentadol Extended Release for the Management of Chronic Low Back Pain: Results of a Prospective, Randomized Double-Blind, Placebo- and Active-Controlled Phase III Study,\"",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2010, 11(11):1787-804; published erratum appears in",
"      <i>",
"       Expert Opin Pharmacother",
"      </i>",
"      , 2010, 11(16):2773.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/20/27975/abstract-text/20578811/pubmed\" id=\"20578811\" target=\"_blank\">",
"        20578811",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hartrick C, Van Hove I, Stegmann JU, et al, &ldquo;Efficacy and Tolerability of Tapentadol Immediate Release and Oxycodone HCl Immediate Release in Patients Awaiting Primary Joint Replacement Surgery for End-Stage Joint Disease: A 10-Day, Phase III, Randomized, Double-Blind, Active- and Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Clin Ther,",
"      </i>",
"      2009, 31(2):260-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/20/27975/abstract-text/19302899/pubmed\" id=\"19302899\" target=\"_blank\">",
"        19302899",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinert R, Lange C, Steup A, et al, &ldquo;Single Dose Analgesic Efficacy of Tapentadol in Postsurgical Dental Pain: The Results of a Randomized, Double-Blind, Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2008, 107(6):2048-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/20/27975/abstract-text/19020157/pubmed\" id=\"19020157\" target=\"_blank\">",
"        19020157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz S, Etropolski M, Shapiro DY, et al, \"Safety and Efficacy of Tapentadol ER in Patients With Painful Diabetic Peripheral Neuropathy: Results of a Randomized-Withdrawal, Placebo-Controlled Trial,\"",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 2011, 27(1):151-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/20/27975/abstract-text/21162697/pubmed\" id=\"21162697\" target=\"_blank\">",
"        21162697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wild JE, Grond S, Kuperwasser B, et al, \"Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain,\"",
"      <i>",
"       Pain Pract",
"      </i>",
"      , 2010, 10(5):416-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/20/27975/abstract-text/20602712/pubmed\" id=\"20602712\" target=\"_blank\">",
"        20602712",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9511 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-C815FD8784-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27975=[""].join("\n");
var outline_f27_20_27975=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13210109\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878273\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12785498\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083927\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878389\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878390\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878324\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878325\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878394\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12809985\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083931\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16327977\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878271\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874994\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878392\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083929\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083925\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878285\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878279\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878280\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300104\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878927\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878303\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878274\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878275\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878277\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878278\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878391\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321931\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15040860\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992810\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878306\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7878308\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9511\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9511|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/13/40149?source=related_link\">",
"      Tapentadol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_20_27976="Treatment of chronic myeloid leukemia in accelerated phase";
var content_f27_20_27976=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of chronic myeloid leukemia in accelerated phase",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27976/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27976/contributors\">",
"     Robert S Negrin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27976/contributors\">",
"     Charles A Schiffer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27976/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27976/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27976/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27976/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/20/27976/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the Philadelphia chromosome t(9;22)(q34;q11)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the BCR-ABL fusion gene. This genetic abnormality results in the formation of a unique gene product (BCR-ABL), which results in a constitutively active tyrosine kinase. It is this deregulated tyrosine kinase that is implicated in the development of CML and is the target of current therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=see_link\">",
"     \"Molecular genetics of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    mesylate was the first tyrosine kinase inhibitor used in the treatment of CML. Since then, several other tyrosine kinase inhibitors have been developed and tested in patients with CML, most notably",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CML has historically been a triphasic disease. Approximately 85 to 90 percent of patients present in a chronic stable phase. Without treatment, this inevitably progresses to a more aggressive, accelerated phase and then culminates in a very difficult to treat blast crisis. As advances are made in the treatment of chronic phase CML, fewer patients (approximately 6 percent at five years) are progressing to accelerated phase and blast crisis. In addition, 10 to 15 percent of patients will initially present in accelerated phase or blast crisis. Interestingly, some patients progress to blast crisis without a clinically discernible accelerated phase. This is supported by an analysis of gene expression profiles in different stages of CML demonstrated relatively distinct patterns in chronic and blast phases without an identifiable &ldquo;signature&rdquo; of accelerated phase suggesting that CML is biologically more likely to be a &ldquo;bi&rdquo; rather than a triphasic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of CML in accelerated phase is discussed here. The treatment of CML in chronic phase or blast crisis is discussed separately as is the use of hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link\">",
"     \"Overview of the treatment of chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION OF ACCELERATED PHASE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Varying definitions have been applied to the accelerated phase of CML (",
"    <a class=\"graphic graphic_table graphicRef60902 \" href=\"UTD.htm?21/53/22364\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/2\">",
"     2",
"    </a>",
"    ]. The most frequently used criteria from the World Health Organization (WHO) define the accelerated phase in patients with CML by the presence of one or more of the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      10 to 19 percent blasts in the peripheral blood or bone marrow",
"     </li>",
"     <li>",
"      Peripheral blood basophils &ge;20 percent",
"     </li>",
"     <li>",
"      Platelets",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL,",
"      </span>",
"      unrelated to therapy",
"     </li>",
"     <li>",
"      Platelets",
"      <span class=\"nowrap\">",
"       &gt;1,000,000/microL,",
"      </span>",
"      unresponsive to therapy",
"     </li>",
"     <li>",
"      Progressive splenomegaly and increasing white cell count, unresponsive to therapy",
"     </li>",
"     <li>",
"      Cytogenetic evolution (defined as the development of chromosomal abnormalities in addition to the Philadelphia chromosome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a patient progresses from chronic to accelerated phase CML their disease is much more difficult to control. Among patients who have",
"    <strong>",
"     not",
"    </strong>",
"    received a BCR-ABL tyrosine kinase inhibitor (TKI), treatment options for accelerated phase CML include TKIs and allogeneic hematopoietic cell transplantation (HCT). Eligibility criteria for allogeneic HCT vary by institution.",
"   </p>",
"   <p>",
"    A small percentage of patients initially treated with a TKI for chronic phase disease will progress to accelerated phase. In addition, many patients initially treated with a TKI for accelerated phase disease will have resistance. Both of these patient groups should undergo testing for BCR-ABL kinase mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/3\">",
"     3",
"    </a>",
"    ]. Mutations are detected in approximately 50 percent of these patients. The mechanisms of resistance in the other patients are poorly understood. A more detailed discussion of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    resistance can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of the treatment of chronic myeloid leukemia\", section on 'Evaluation at loss of response'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patients eligible for HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with accelerated phase CML who are candidates for HCT, we recommend initial therapy with a tyrosine kinase inhibitor (TKI;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ) followed by HCT rather than initial HCT. Despite the risks of short-term morbidity and mortality, allogeneic HCT is potentially curative in accelerated phase. The most important prognostic factor for survival following allogeneic HCT for CML is the disease phase at the time of transplantation, with four-year disease-free survival (DFS) rates of 30 to 40 percent in patients with accelerated phase versus up to 80 percent in patients with chronic phase disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Given this disparity between survival of patients in different disease phases, it is logical to attempt to bring a patient from accelerated phase to chronic phase or even into remission by treatment with a TKI prior to transplantation. Therefore, a search for a donor should be begun at the time that accelerated phase is diagnosed.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    given at a dose of 600 mg by mouth daily results in overall response rates of 70 percent with 20 percent of patients returning to a second chronic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/6\">",
"     6",
"    </a>",
"    ]. Imatinib does not appear to increase rates of morbidity and mortality with the subsequent transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/7\">",
"     7",
"    </a>",
"    ]. Trials supporting the use of imatinib in accelerated phase CML are described in detail in the following section. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Patients ineligible for HCT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The optimal timing of transplantation in patients in accelerated phase in the era of TKIs is unknown. When patients undergo initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , the principal options are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transplantation after the best response has been achieved.",
"     </li>",
"     <li>",
"      Initial treatment with a TKI followed by treatment with another TKI at relapse followed by transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been no randomized trials comparing HCT to treatment with a TKI. The main data come from retrospective analyses and clinical experience. As an example, a retrospective analysis of 132 patients with accelerated phase CML examined outcomes among those treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy alone or a short course of imatinib followed by allogeneic HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/8\">",
"     8",
"    </a>",
"    ]. When compared with imatinib therapy alone, imatinib therapy followed by allogeneic HCT resulted in significantly longer event-free survival (72 versus 39 percent), overall survival (83 versus 51 percent), and progression-free survival (95 versus 48 percent) at six years. Of note, this was an analysis of a heterogeneous mixture of patients and that patients treated with imatinib alone were older, had received more prior treatment, and had higher risk clinical features. Indeed, there was no difference in outcome in a small subset of patients felt to have lower risk disease.",
"   </p>",
"   <p>",
"    We suggest transplantation once a maximum response to a TKI has been realized. The rationale for this approach is that success with HCT is most likely in patients with relatively quiescent disease. There are no data comparing continuation of a TKI versus transplantation in the relatively small group of patients in whom a complete cytogenetic response is obtained with TKI treatment. There is concern, however, that if HCT is postponed until a second TKI is required for relapse, the chance of inducing a similar level of response is lower. The studies that have examined the use of TKIs in accelerated disease are discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Patients ineligible for HCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with accelerated phase CML who are not candidates for HCT, we recommend initial therapy with a tyrosine kinase inhibitor (TKI). For such patients who respond to a TKI, we recommend continuing the TKI as long as they continue to respond in the hope that the responses will be durable. A detailed discussion on the risk of discontinuing treatment in responding patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Aims of initial therapy and duration of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with accelerated phase CML treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , we recommend the use of the 600 mg daily starting dose of imatinib rather than the 400 mg daily starting dose used for patients with chronic phase CML. This is based upon significantly higher response rates and survival at 12 months as noted in a number of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/6,9-11\">",
"     6,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the development of TKIs, interferon alpha plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    was used as the initial treatment of choice for patients with CML who were not candidates for transplantation. Treatment of patients in accelerated phase with interferon alpha-based regimens resulted in overall response rates of 20 to 30 percent with rare cytogenetic responses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The randomized IRIS trial demonstrated the superiority of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    over interferon plus cytarabine in previously untreated patients with CML in chronic phase [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Although no such direct comparison is available for patients in accelerated phase, extrapolation of these results in chronic phase along with historical comparisons in accelerated phase and the results of phase II trials in patients with accelerated phase disease, have lead to the use of a TKI as the initial therapy of choice.",
"   </p>",
"   <p>",
"    The following is a survey of reports on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    in accelerated phase CML [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/9-11,16,17\">",
"     9-11,16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A historical comparison evaluated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      compared with interferon alpha based therapy in accelerated phase CML [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/10\">",
"       10",
"      </a>",
"      ]. Imatinib resulted in improved rates of complete hematologic (82 versus &le;50 percent) and cytogenetic (43 versus &le;6 percent) responses and improved four-year overall survival (60 to 88 versus &lt;30 percent).",
"     </li>",
"     <li>",
"      A phase II trial examined the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      in 200 patients with CML in accelerated phase [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/6,9,10\">",
"       6,9,10",
"      </a>",
"      ]. An overall clinical response rate of 90 percent was seen with a complete cytogenetic response rate of 24 percent. Drug discontinuation for severe toxicity was needed in 3 percent of patients. A critical part of this study was the comparison of a 400 mg dose (given to the initial cohort of patients) versus a 600 mg daily starting dose, given to the subsequent group of patients. The 600 mg dose had significantly higher rates of complete hematologic response (37 versus 27 percent), complete cytogenetic response (19 versus 11 percent) and survival at 12 months (78 versus 65 percent). (",
"      <a class=\"graphic graphic_figure graphicRef66546 \" href=\"UTD.htm?37/26/38319\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      An analysis (only published in abstract form) that included patients from the above study and two other phase II studies evaluated the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      600 mg daily in 235 patients with accelerated phase disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/11\">",
"       11",
"      </a>",
"      ]. At 36 months after initiation of imatinib, an estimated 55 percent of patients were alive and 40 percent were progression-free. Improved three-year survival rates (85 versus 52 percent) were seen in patients with a major cytogenetic response at three months when compared with patients who had no such response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT OF DISEASE RESISTANT TO INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with accelerated phase disease resistant to initial therapy include both patients who present with accelerated phase disease and fail to benefit from a TKI and those who progress from chronic to accelerated phase disease despite therapy with a TKI. For such patients, the choice of subsequent treatment depends upon the result of BCR-ABL kinase mutation analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Y253H,",
"      <span class=\"nowrap\">",
"       E255K/V,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       F359V/C/I",
"      </span>",
"      mutations are resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      but sensitive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       F317L/V/I/C,",
"      </span>",
"      V299L, and T315A mutations are sensitive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      but shows intermediate sensitivity to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Those who have a T315I mutation will not respond to treatment with most of the available TKIs.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     Ponatinib",
"    </a>",
"    is the only TKI with significant activity in such patients. Ponatinib, HCT, or enrollment in a clinical trial would be appropriate choices for such patients. For patients who do not have a T315I mutation, we recommend the use of another TKI. The choice of agent may be made based upon side effect profiles and knowledge of co-morbid conditions in an individual patient. We suggest that this treatment be followed by an allogeneic HCT in eligible patients.",
"   </p>",
"   <p>",
"    Although patient noncompliance is not a common cause of progression in patients with accelerated phase, it is important to ask patients with apparent resistance about their compliance with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    dose and schedule and the use of other medications or herbal supplements which may impair the metabolism of the imatinib. Imatinib blood levels can be measured if there are questions about an individual's compliance with the medication. More details on the potential interactions between tyrosine kinase inhibitors and other medications and herbs are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\", section on 'Dosing and drug interactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The second generation TKIs were initially tested in patients who had failed to benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    therapy. As described below, approximately 30 to 40 percent of these patients will have responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    . The use of any of these agents is acceptable. There are no randomized trials comparing these agents with each other, and available data indicate that the response rates to these agents are similar. In the future, the choice of a second generation TKI may depend upon whether a particular BCR-ABL mutation, if present, is sensitive in vitro and, more importantly, clinically, to this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. Notable examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The T315I mutation has shown resistance to most available TKIs.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"       Ponatinib",
"      </a>",
"      is the only TKI with significant activity in such patients.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=see_link\">",
"       Omacetaxine",
"      </a>",
"      has also been approved for treatment of patients with the T315I mutation. Alternatives are to proceed to transplantation or try an investigational agent as part of a clinical trial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H15#H15\">",
"       \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Clinical trials'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Y253H,",
"      <span class=\"nowrap\">",
"       E255K/V,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       F359V/C/I",
"      </span>",
"      mutations are resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      but sensitive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       F317L/V/I/C,",
"      </span>",
"      V299L, and T315A mutations are sensitive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"       nilotinib",
"      </a>",
"      but shows intermediate sensitivity to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"       dasatinib",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At this time, the choice of a second generation TKI for most patients is dependent upon drug side effect profile and patient co-morbidities.",
"   </p>",
"   <p>",
"    The data supporting the use of these two agents in accelerated phase disease are presented in the following sections. There appears to be a significant relapse rate in patients in accelerated phase even after successful treatment with second generation TKIs and so it is appropriate to begin a donor search when therapy with these TKIs are initiated in patients with accelerated phase and to consider transplantation once a response is obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=see_link\">",
"     \"Hematopoietic cell transplantation in chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dasatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     Dasatinib",
"    </a>",
"    is approved in the United States for the treatment of adults with accelerated phase CML with resistance to or intolerance of prior therapy, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . Approved doses include both 70 mg twice daily and 140 mg once daily. A subset analysis of 317 patients with accelerated phase CML resistant or intolerant to imatinib who were included in a randomized prospective trial of dasatinib 140 mg once daily versus 70 mg twice daily reported similar response rates, but decreased toxicity with the once daily dose [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/20\">",
"     20",
"    </a>",
"    ]. Patients assigned to once-daily treatment had significantly fewer pleural effusions (20 versus 39 percent). At a median follow-up of 15 months, overall rates of complete hematologic, major cytogenetic, and complete cytogenetic response were 50, 41, and 32 percent, respectively.",
"   </p>",
"   <p>",
"    A phase 2, open-label, single-arm clinical trial examined the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    70 mg twice daily in 74 patients with accelerated phase CML who were resistant to (161 patients) or intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. After 14 months of follow-up, the following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major hematologic (64 percent), complete hematologic (45 percent), and complete cytogenetic (32 percent) responses were observed.",
"     </li>",
"     <li>",
"      Sixty-six percent of patients were progression-free at 12 months. However, the progression-free survival curves appeared to show a steady decline over that time suggesting that such patients should also be considered for allogeneic HCT if eligible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Nilotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     Nilotinib",
"    </a>",
"    is approved in the United States for the treatment of adults with accelerated phase CML with resistance or intolerance to prior therapy, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    . The approved dose is 400 mg twice daily.",
"   </p>",
"   <p>",
"    A phase I dose-escalation study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    included 46 patients with accelerated phase",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    -resistant CML and showed hematologic and cytogenetic response rates of 33 and 22 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase II study examined the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    in 119 patients with accelerated phase CML and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    resistance (81 percent) or intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients received nilotinib 400 mg twice daily with escalation to 600 mg twice daily for inadequate response. Results included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      47 percent of patients achieved a hematologic response (26 percent complete hematologic response rate) and 29 percent had a major cytogenetic response (16 percent complete). One-year overall survival was 79 percent.",
"     </li>",
"     <li>",
"      Grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      side effects included thrombocytopenia (35 percent), neutropenia (21 percent), and increased lipase (18 percent).",
"     </li>",
"     <li>",
"      On further follow-up, 66 percent of patients who achieved a major cytogenetic response maintained this response at 24 months [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/25\">",
"       25",
"      </a>",
"      ]. The estimated overall and progression-free survival rates at 24 months were 70 and 33 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     Nilotinib",
"    </a>",
"    does not have activity in the highly resistant T315I mutation and is often overcome by the Y253H and",
"    <span class=\"nowrap\">",
"     E255V/K",
"    </span>",
"    mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Treatment with nilotinib has been associated with reversible, usually asymptomatic elevations in unconjugated bilirubin, lipase, and amylase. Detailed information on drug toxicity and management of side effects is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=see_link\">",
"     \"Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15773151\">",
"    <span class=\"h2\">",
"     Bosutinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     Bosutinib",
"    </a>",
"    is approved in the United States for the treatment of adults with accelerated phase CML with resistance or intolerance to prior therapy. The approved dose is 500 mg once daily.",
"   </p>",
"   <p>",
"    Preliminary results are available for phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     bosutinib",
"    </a>",
"    in 546 patients with CML with resistance or intolerance to at least one tyrosine kinase inhibitor that included 69 patients with accelerated phase CML [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/28\">",
"     28",
"    </a>",
"    ]. At a minimum follow-up of 12 months, 55 percent achieved a hematologic response (30 percent complete hematologic response). The most common severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities included diarrhea (9 percent), rash (9 percent), and vomiting (3 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/45/23254?source=see_link\">",
"     Bosutinib",
"    </a>",
"    does not have activity against the highly resistant T315I mutation. Bosutinib is also being studied in patients with newly diagnosed CML in chronic phase and in patients with chronic phase or blast crisis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H1349640#H1349640\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Bosutinib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=see_link&amp;anchor=H15772961#H15772961\">",
"     \"Initial treatment of chronic myeloid leukemia in chronic phase\", section on 'Bosutinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12150432\">",
"    <span class=\"h2\">",
"     Ponatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     Ponatinib",
"    </a>",
"    is an orally administered BCR-ABL inhibitor that has demonstrated activity against the native and mutated BCR-ABL proteins, including the T315I mutation. Ponatinib received accelerated approval by the US Food and Drug Administration for the treatment of CML in adults with resistance or intolerance to prior tyrosine kinase inhibitor therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/29\">",
"     29",
"    </a>",
"    ]. The recommended dose and schedule is 45 mg orally once daily with or without food. Approval was accompanied by a boxed warning alerting patients and clinicians that arterial thrombosis and liver toxicity have occurred in patients treated with ponatinib.",
"   </p>",
"   <p>",
"    Preliminary results of the phase II PACE trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    reported major hematologic responses (MHR) in 52 percent of the 83 patients with accelerated phase CML resistant or intolerant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    , including patients with T315I mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/30\">",
"     30",
"    </a>",
"    ]. Median time to MHR and median duration of MHR were 21 days and 9.5 months, respectively. The most common toxicities were thrombocytopenia, rash, dry skin, abdominal pain, and headache. Overall, severe adverse events led to the discontinuation of therapy in 11 percent of patients.",
"   </p>",
"   <p>",
"    Data regarding the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"     ponatinib",
"    </a>",
"    in chronic phase or blast crisis CML are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H12149527#H12149527\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Ponatinib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of chronic myeloid leukemia in blast crisis\", section on 'Treatment after failure of initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24874649\">",
"    <span class=\"h2\">",
"     Omacetaxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=see_link\">",
"     Omacetaxine",
"    </a>",
"    mepesuccinate (previously known as homoharringtonine) is a protein synthesis inhibitor approved by the US Food and Drug Administration for the treatment of accelerated phase CML in adults with resistance or intolerance to two or more TKIs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/31\">",
"     31",
"    </a>",
"    ]. The recommended dose and schedule is 1.25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    subcutaneous injection twice daily for 14 days of a 28-day cycle for the induction phase and 1.25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    subcutaneous injection twice daily for 7 days of a 28-day cycle for maintenance.",
"   </p>",
"   <p>",
"    Preliminary results were reported from a phase II trial that investigated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=see_link\">",
"     omacetaxine",
"    </a>",
"    in 35 patients with accelerated phase CML resistant to an initial TKI [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27976/abstract/31\">",
"     31",
"    </a>",
"    ]. Of these, 22 (63 percent) had received prior treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/39/22136?source=see_link\">",
"     dasatinib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/1/29720?source=see_link\">",
"     nilotinib",
"    </a>",
"    . Subcutaneous omacetaxine (1.25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    was administered twice daily on days 1 through 14 of a 28-day cycle until hematologic response or a maximum of six cycles. Patients who achieved a hematologic response were then treated twice daily on days 1 through 7 of a 28-day cycle as maintenance. Four patients (11 percent) achieved a complete hematologic response and one additional patient had less than 5 percent blasts on bone marrow examination. The median time to response was 2.3 months and the median duration of response was 4.7 months. Common toxicities included thrombocytopenia, neutropenia, anemia, infection, diarrhea, nausea, pyrexia, fatigue, asthenia, and arthralgia.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/13/13526?source=see_link\">",
"     omacetaxine",
"    </a>",
"    in patients with chronic phase disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=see_link&amp;anchor=H24874435#H24874435\">",
"     \"Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy\", section on 'Omacetaxine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=see_link\">",
"       \"Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As advances are made in the treatment of chronic phase chronic myeloid leukemia (CML), fewer patients (approximately 7 percent at five years) are progressing to accelerated phase or blast crisis. In addition, 10 to 15 percent of patients will initially present in accelerated phase or blast crisis and it is likely that a larger fraction of patients will present in more advanced stages in less medically-developed countries. Treatment of these more advanced phases of CML is difficult. In general, an attempt is made to return the patient to a chronic phase with plans to proceed to allogeneic hematopoietic cell transplantation (HCT) after an initial response.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with newly diagnosed CML in accelerated phase, we recommend initial treatment with a BCR-ABL tyrosine kinase inhibitor (TKI) rather than initial HCT (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Specifically for patients who choose initial therapy with imatinib, we recommend imatinib 600 mg by mouth daily rather than 400 mg daily (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Initial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no good data comparing HCT versus continued TKI in patients who demonstrate a deep initial response to TKI therapy. For patients with CML in accelerated phase who are eligible for HCT, we suggest referral for HCT during their treatment with a TKI, including those who achieve a complete cytogenetic response (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A search for a donor should be begun at the time that accelerated phase is diagnosed. We believe proceeding to HCT maximizes the chance of cure. However, patients who wish to minimize short-term morbidity and mortality might choose to defer HCT until after evidence of progression or intolerance to a TKI. Such a relapse would likely require treatment with another TKI prior to HCT. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Patients eligible for HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For responding patients without donors, those who are not suitable for transplantation, and those who refuse transplantation, we recommend continuing a TKI indefinitely in the hope that the responses will be durable (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Patients ineligible for HCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with accelerated phase CML refractory to or intolerant of an initial TKI who do not have a T315I mutation, we recommend the use of another TKI (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The choice of agent may be based upon side effect profiles and knowledge of comorbid conditions and BCR-ABL mutational analysis in an individual patient. We suggest that this treatment be followed by an allogeneic HCT in HCT eligible patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of disease resistant to initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with accelerated phase CML in whom an initial TKI is not successful and have a T315I mutation, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/55/2935?source=see_link\">",
"       ponatinib",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest that this treatment be followed by an allogeneic HCT in HCT eligible patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12150432\">",
"       'Ponatinib'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/1\">",
"      Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006; 103:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/2\">",
"      Cortes JE, Talpaz M, O'Brien S, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 2006; 106:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/3\">",
"      Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011; 118:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/4\">",
"      Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. Blood 1994; 84:4368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/5\">",
"      Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/6\">",
"      Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/7\">",
"      Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/8\">",
"      Jiang Q, Xu LP, Liu DH, et al. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Blood 2011; 117:3032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/9\">",
"      Kantarjian HM, O'Brien S, Cortes JE, et al. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002; 8:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/10\">",
"      Kantarjian H, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer 2005; 103:2099.",
"     </a>",
"    </li>",
"    <li>",
"     Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase, accelerated phase, or blast crisis chronic myeloid leukemia treated with imatinib in three large phase II trials (abstract). Blood 2004; 104:abstract 23.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/12\">",
"      Kantarjian HM, Smith TL, O'Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995; 122:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/13\">",
"      Kantarjian HM, Keating MJ, Estey EH, et al. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol 1992; 10:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/14\">",
"      O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/15\">",
"      Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/16\">",
"      O'Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002; 100:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/17\">",
"      Rea D, Etienne G, Nicolini F, et al. First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia. Leukemia 2012; 26:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/18\">",
"      O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/19\">",
"      Fava C, Kantarjian HM, Jabbour E, et al. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 2009; 113:5058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/20\">",
"      Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009; 113:6322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/21\">",
"      Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol 2009; 27:3472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/22\">",
"      Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007; 109:4143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/23\">",
"      Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006; 354:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/24\">",
"      le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008; 111:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/25\">",
"      le Coutre PD, Giles FJ, Hochhaus A, et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012; 26:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/26\">",
"      Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 2006; 108:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/27\">",
"      von Bubnoff N, Manley PW, Mestan J, et al. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006; 108:1328.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203341lbl.pdf (Accessed on September 05, 2012).",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf?et_cid=30657199&amp;et_rid=463648356&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203469lbl.pdf (Accessed on December 17, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27976/abstract/30\">",
"      Kantarjian HM, Kim DW, Pinilla-Ibarz J, et al. Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial (abstract 915). ASH Annual Meeting Abstracts 2012; 120:915.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf?et_cid=30334780&amp;et_rid=463648356&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203585lbl.pdf (Accessed on October 26, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4514 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-190.81.197.98-68DAC4FE3C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27976=[""].join("\n");
var outline_f27_20_27976=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION OF ACCELERATED PHASE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patients eligible for HCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patients ineligible for HCT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT OF DISEASE RESISTANT TO INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dasatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Nilotinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15773151\">",
"      Bosutinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12150432\">",
"      Ponatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24874649\">",
"      Omacetaxine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4514\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4514|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/26/38319\" title=\"figure 1\">",
"      OS imatinib AP CML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4514|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/53/22364\" title=\"table 1\">",
"      Accel phase CML criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27290?source=related_link\">",
"      Clinical use of tyrosine kinase inhibitors for chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33066?source=related_link\">",
"      Hematopoietic cell transplantation in chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7034?source=related_link\">",
"      Initial treatment of chronic myeloid leukemia in chronic phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31512?source=related_link\">",
"      Molecular genetics of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/16/41225?source=related_link\">",
"      Overview of the treatment of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/60/37829?source=related_link\">",
"      Patient information: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7816?source=related_link\">",
"      Treatment of chronic myeloid leukemia in blast crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20762?source=related_link\">",
"      Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_20_27977="Pathobiology of multiple myeloma";
var content_f27_20_27977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathobiology of multiple myeloma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27977/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27977/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27977/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27977/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27977/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27977/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/20/27977/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for approximately 10 percent of all hematologic malignancies. It is an incurable disease and the cause of about 20 percent of deaths from hematologic malignancy and 2 percent of deaths from all cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MM is thought to evolve from an asymptomatic pre-malignant stage of clonal plasma cell proliferation termed monoclonal gammopathy of undetermined significance (MGUS). MGUS is present in over 3 percent of the population above the age of 50, and progresses to myeloma or a related malignancy at a rate of 1 percent per year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While MGUS is asymptomatic, MM is characterized by end organ damage, which includes hypercalcemia, renal dysfunction, anemia, or lytic bone lesions. In some patients, an intermediate asymptomatic but more advanced pre-malignant stage referred to as smoldering multiple myeloma (SMM) can be recognized clinically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H3#H3\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Smoldering (asymptomatic) multiple myeloma (SMM)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathobiology of MM will be reviewed here. The clinical and laboratory manifestations, diagnosis, and treatment of MM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CELL OF ORIGIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;MM appears to arise from the malignant transformation of post-germinal center plasma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The post-germinal ancestry of these cells is principally supported by the identification of somatic mutations in the variable region of the immunoglobulin genes, which serve as a marker of germinal center transit. These cells also display ongoing somatic mutations, which reflect the pressure of antigen selection encountered by post-germinal center lymphocytes. By definition, class switching is demonstrated in IgG and IgA MM, but not in IgM MM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunoglobulin genetics\", section on 'Immunoglobulin class-switching'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The malignant plasma cells of MM have a low proliferative rate and have generally been unable to sustain tumor growth in vivo, suggesting that precursor cells are responsible for proliferation of the malignant cell population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. It has been proposed that these abnormal precursor B-cells originate in the lymph nodes and migrate to the bone marrow, which provides a microenvironment conducive to terminal plasma cell differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/6\">",
"     6",
"    </a>",
"    ]. This could explain the observation that the malignant plasma cells appear to be restricted to the microenvironment of the bone marrow, even though the disease is widely disseminated throughout the axial skeleton. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Bone marrow microenvironment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathobiology of MM is a complex process leading to the replication of a malignant clone of plasma cell origin. While some steps in this pathway have been elucidated, many remain unknown. Virtually all MM cases are preceded by a premalignant plasma cell proliferative disorder known as monoclonal gammopathy of undetermined significance (MGUS) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/7\">",
"     7",
"    </a>",
"    ]. MGUS is present in over 3 percent of the population above the age of 50, and progresses to myeloma or a related malignancy at a rate of 1 percent per year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of MM can be conceptualized as two sequential processes (",
"    <a class=\"graphic graphic_figure graphicRef78232 \" href=\"UTD.htm?9/59/10166\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establishment of MGUS &mdash; While the inciting event is unknown, MGUS appears to develop as the result of cytogenetic abnormalities, many of which are thought to be the product of an abnormal plasma cell response to antigenic stimulation. The result is a plasma cell clone producing monoclonal immunoglobulin.",
"     </li>",
"     <li>",
"      Progression from MGUS to MM &mdash; Further insults to the plasma cell clone, either through additional genetic abnormalities or changes in the bone marrow microenvironment, result in the progression of MGUS to MM.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some patients, an intermediate asymptomatic but more advanced pre-malignant stage referred to as smoldering multiple myeloma can be recognized clinically. These patients may have been diagnosed in the midst of progressing from MGUS to MM, or may represent biologic MGUS with a higher baseline clonal plasma cell burden.",
"   </p>",
"   <p>",
"    Once the clonal plasma cell population is created and progresses to MM, patients develop symptoms (eg, hypercalcemia, lytic bone lesions, renal dysfunction, and anemia) related to the infiltration of plasma cells into the bone or other organs or to kidney damage from excess light chains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ESTABLISHMENT OF MGUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step in the pathway to the development of MM is the establishment of the premalignant plasma cell proliferative disorder known as monoclonal gammopathy of undetermined significance (MGUS). Patient-related and environmental risk factors for MGUS have been proposed, but the exact cause of MGUS development remains elusive.",
"   </p>",
"   <p>",
"    Similar patterns of certain cytogenetic abnormalities can be found in the clonal plasma cells of MGUS and MM. These cytogenetic abnormalities (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Cytogenetic abnormalities'",
"    </a>",
"    below) are thought to lead to the creation of a plasma cell clone. While the event leading to these genetic changes likely varies, the most likely process is abnormal plasma cell response to antigenic stimulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic data suggest a genetic predisposition as well as other potential risk factors including older age, immunosuppression, and environmental exposures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/8-12\">",
"     8-12",
"    </a>",
"    ]. Hormonal factors may play a role, since women have significantly lower age-specific prevalence rates when compared with men.",
"   </p>",
"   <p>",
"    A genetic predisposition is predominantly supported by the findings that the incidence of MGUS varies by ethnicity and that a small, but unknown, fraction of cases are familial. Such cases may be due to either shared genes or environmental factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exposure to radiation, benzene, and other organic solvents, herbicides, and insecticides may also play a role. However, the number of cases reported for each of these risk factors is small. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Data regarding the risk of MM among atomic bomb survivors are mixed. Some studies note that an increased risk of MM is found in atomic bomb survivors exposed to more than 50 rad, those &lt;20 years of age, and those in close proximity to the bomb [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/8,9\">",
"       8,9",
"      </a>",
"      ], while others have concluded that there was little evidence of an increased risk of MM after atomic bomb exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiologists exposed to large doses of long-term radiation have an increased risk of MM [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Workers in nuclear plants and farmers who use herbicides and insecticides and those who employ benzene and petroleum products may have increased rates of MM, but the evidence is not compelling [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While further data are necessary for a definitive statement regarding these risk factors, it is prudent to limit exposure to these agents for this and other reasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cytogenetic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cytogenetic abnormalities appear to play a major role in the development of MGUS. Most, if not all, cases of MGUS and MM have chromosomal abnormalities that can be detected by fluorescence in situ hybridization (FISH), multicolor spectral karyotyping, comparative genomic hybridization, or gene expression profiling [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. The percentage of cases demonstrating each abnormality varies by the detection method used and disease stage. Most cases of MGUS appear to be initiated in conjunction with either translocation events involving the immunoglobulin heavy chain (IgH) locus or genetic instability manifested by hyperdiploidy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Immunoglobulin heavy chain translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial immune response (primary immune response) results in formation of IgM antibodies targeting the offending antigen. When exposed to the same antigen again, there may be a \"class switch\" that occurs wherein the genes coding for the variable portion of the immunoglobulin heavy chain (IgH) switch from the gene coding for the constant region of IgM to move next to the gene coding for the constant region of IgG (or IgA). This is termed \"switch recombination\" or \"class switching,\" as a result of which the antibody made by the plasma cell changes from IgM type to IgG or IgA (secondary immune response). Approximately half of MGUS cases are likely caused by translocation events (errors) that occur at the time of immunoglobulin switch recombination. These translocations affect the immunoglobulin heavy chain (IgH) locus on chromosome 14q32, and result in the juxtaposition of an oncogene next to the IgH locus. This results in the aberrant expression of the affected oncogene and is thought to be a critical step in the development of MGUS. Cases that include these rearrangements are referred to as IgH translocated MGUS or non-hyperdiploid MGUS. The most common partner chromosome loci and genes dysregulated in these translocations are (",
"    <a class=\"graphic graphic_table graphicRef52114 \" href=\"UTD.htm?39/26/40363\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      11q13 &mdash; cyclin D1 gene",
"     </li>",
"     <li>",
"      6p21 &mdash; cyclin D3 gene",
"     </li>",
"     <li>",
"      4p16.3 &mdash; multiple myeloma set domain (MMSET)",
"     </li>",
"     <li>",
"      16q23 &mdash; musculoaponeurotic fibrosarcoma (c-maf)",
"     </li>",
"     <li>",
"      20q11 &mdash; musculoaponeurotic fibrosarcoma oncology family, protein B (mafB)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The juxtaposition of these oncogenes next to the IgH locus results in overexpression of the oncogene induced by the active promoter region of the IgH genes. The products of this translocation then act as transcription factors, growth factor receptors, and cell cycle mediators to promote growth and replication. This process establishes the MGUS clone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link&amp;anchor=H3#H3\">",
"     \"Immunoglobulin genetics\", section on 'Immunoglobulin gene rearrangement'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44054?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathobiology of mantle cell lymphoma\", section on 'Cyclin D1 expression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The percentage of cases displaying IgH translocations increases as the disease progresses from MGUS to MM. IgH translocations are found in nearly 50 percent of patients with MGUS or smoldering MM, 55 to 73 percent of those with MM, 85 percent of plasma cell leukemias, and &gt;90 percent of in vitro human myeloma cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This may reflect the fact that certain types of IgH translocated MGUS and MM (eg, t14;16, t14;20) may be more aggressive than the hyperdiploid type of MGUS (see below)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Hyperdiploidy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of MGUS cases that do not have translocations involving IgH (IgH non-translocated MGUS, also called hyperdiploid MGUS) demonstrate genetic instability manifested by hyperdiploidy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/20,26-31\">",
"     20,26-31",
"    </a>",
"    ]. Hyperdiploidy refers to the gain of numerous chromosomes (trisomies) in the clonal cell population. Hyperdiploidy in MM typically involves one or more odd numbered chromosomes, with the exception of chromosomes 1, 13, and 21. Hyperdiploidy can result in the overexpression of genes located on the affected chromosomes. These genes may promote growth and replication leading to the MGUS clone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Aberrant response to antigenic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The events that trigger the cytogenetic abnormalities described above (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Cytogenetic abnormalities'",
"    </a>",
"    above) are not known, but it is felt that the trigger for such changes is related to antigenic stimulation. The reason why an antigenic stimulus (the nature of which is yet unknown) produces an abnormal, sustained, proliferative signal for plasma cells is unclear. Nevertheless, the increase in the proliferative rate of these plasma cells then increases the risk for chromosomal damage that evades the standard repair mechanisms. The resultant chromosomal changes are then thought to lead to the creation of a plasma cell clone responsible for the overproduction of a single type of immunoglobulin. It is this monoclonal immunoglobulin that is detected and identifies MGUS as an entity. Potential mechanisms for this enhanced response to",
"    <span class=\"nowrap\">",
"     infection/exposure",
"    </span>",
"    include the abnormal expression of toll-like receptors (TLRs) and overexpression of IL-6 receptors in plasma cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=see_link\">",
"     \"Immunoglobulin genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Toll like receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toll-like receptors (TLRs) are molecules on the cell surface that detect and respond to microbial infection. They are a component of our non-specific or \"innate\" immune defense and act as receptors that recognize molecular patterns on antigens. The ligands for these receptors are components of pathogenic microbes and are often called \"pathogen-associated molecular patterns\" (PAMPs). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In vitro studies show that human myeloma cell lines and primary myeloma cells express a broad range of TLRs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/32\">",
"     32",
"    </a>",
"    ]. TLR-specific ligands cause increased myeloma cell proliferation, survival, and resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    induced apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Response to interleukin 6",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin 6 (IL-6) is a cytokine that encourages the growth and survival of both normal and abnormal plasma cells. IL-6 appears to be required for the survival of myeloma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When compared with normal plasma cells, plasma cells in MGUS demonstrate overexpression of the IL-6 receptor alpha-chain (CD126) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In vitro studies have demonstrated that inhibition of IL-6 stops myeloma cell lines from proliferating [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In vivo, IL-6 is produced by the bone marrow microenvironment and acts in a paracrine fashion to stimulate plasma cells. Adhesion of plasma cells to the bone marrow stroma also appears to trigger IL-6 secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/44\">",
"     44",
"    </a>",
"    ]. The sequence of events associated with IL-6 overexpression is not clear. IL-6 stimulation of plasma cells results in the upregulation of Bcl-xL and Mcl-1, factors that enhance plasma cell survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/45\">",
"     45",
"    </a>",
"    ]. Other pathways that may be involved in the IL-6 stimulation of plasma cells include:",
"    <span class=\"nowrap\">",
"     JAK/STAT,",
"    </span>",
"    <span class=\"nowrap\">",
"     ras/MAP",
"    </span>",
"    kinase, and",
"    <span class=\"nowrap\">",
"     JNK/SAPK",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/36,46,47\">",
"     36,46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGRESSION OF MGUS TO MM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since not all patients with MGUS develop MM, the initial genetic changes resulting in MGUS are necessary, but not sufficient for the development of MM. MGUS progresses to symptomatic MM at a consistent annual rate suggesting that this progression may be explained by a \"random second hit\" model [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/48\">",
"     48",
"    </a>",
"    ]. The risk of progression is similar regardless of the known duration of antecedent MGUS, suggesting that the second-hit responsible for progression is a random event, not cumulative damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=see_link&amp;anchor=H22391006#H22391006\">",
"     \"Clinical course and management of monoclonal gammopathy of undetermined significance\", section on 'Disease progression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of progression events may act as this \"second hit\" resulting in an increased tumor burden [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Additional genetic changes (eg, Ras mutations, p16 methylation, p53 mutations)",
"     </li>",
"     <li>",
"      Increased cell proliferation due to cell cycle dysregulation",
"     </li>",
"     <li>",
"      Evasion of programmed cell death (apoptosis)",
"     </li>",
"     <li>",
"      Changes in the bone marrow microenvironment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sequence of events, however, is not clear. The major changes associated with progression are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Secondary cytogenetic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The malignant transformation of MGUS to multiple myeloma likely results from secondary cytogenetic events. While a number of secondary events have been identified, the exact pathogenetic event remains undefined. Secondary cytogenetic events that have been reported in the literature include IgH translocations, deletions at 17p13 (the locus for the p53 tumor suppressor gene), mutations of Ras genes, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/19,49,50\">",
"     19,49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Secondary IgH translocations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A \"secondary IgH translocation\" involving the MYC oncogene (8q24) is seen in a subset of patients with myeloma, and the frequency of this translocation increases with the stage of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/21,51-53\">",
"     21,51-53",
"    </a>",
"    ]. Other secondary translocations that occur less frequently involve 6p25, 20q11, and 1q21 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathobiology of Burkitt lymphoma\", section on 'c-MYC in normal cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Deletion of 17p13",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deletions of 17p13, the p53 locus, are found in 10 percent of MM patients, and are associated with a shorter survival after both conventional and hematopoietic cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/24,55-59\">",
"     24,55-59",
"    </a>",
"    ]. This deletion is highly associated with disease progression, advanced disease stages, plasma cell leukemia, and central nervous system multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/20,60\">",
"     20,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ras mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The N- and K-ras genes encode intracellular signal transducers involved in normal tissue signaling and regulation of proliferation, differentiation, and senescence. When mutated, they act as potent oncogenes. N- and K-ras mutations occur in 10 to 40 percent of MM at diagnosis and are found at higher frequency in advanced and terminal stages of MM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/61\">",
"     61",
"    </a>",
"    ]. Mutations in N-ras or K-ras are associated with a significantly worse survival than those with wild-type ras genes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/62\">",
"     62",
"    </a>",
"    ]. K-ras mutations are more prevalent among patients with t(11;14)(q13;q32) myeloma (50 percent), in contrast to the other primary IgH translocations (&lt;10 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Activation of NF kappa B",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least half of MM cases demonstrate constitutive activation of the NF kappa B pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. Among other roles, NF kappa B acts as a transcription factor regulating osteolytic activity in normal tissue. Constitutive expression results in an imbalance of osteoblastic and osteoclastic activity in the bone resulting in lytic bone lesions. Activity in the NF kappa B pathway can be increased by an upregulation of NF kappa B itself through amplification or chromosomal translocations or as a consequence of the inactivation of suppressors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Osteolytic bone lesions'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cell cycle dysregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased proliferation of clonal plasma cells seen with the progression of MGUS to MM may be due in part to a dysregulation of the cell cycle. Aberrant expression of the cyclin proteins drives cell cycle progression by phosphorylation and inactivation of the retinoblastoma pathway that normally impairs cell cycle progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44054?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathobiology of mantle cell lymphoma\", section on 'Cell cycle progression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are multiple mechanisms that can result in the expression of cyclin proteins in MM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overexpression of cyclin D1, cyclin D2, or cyclin D3 through translocations with the immunoglobulin heavy chain (IgH) locus. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Immunoglobulin heavy chain translocations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Loss of cyclin D kinase inhibitors (CdkI; also known as p15, p16, p18, and p19) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/67,68\">",
"       67,68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CdkI gene inactivation by hypermethylation [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. The cyclin D kinase inhibitors are methylated in nearly 75 percent of MM cases [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]. Methylation of CdkI is associated with an increased proliferation rate of plasma cells and a poor prognosis in MM [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/69\">",
"       69",
"      </a>",
"      ]. In comparison, methylation of p16 or p17 is found in 20 to 35 percent of MGUS cases [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/70\">",
"       70",
"      </a>",
"      ]. This suggests that CdkI methylation may be an early event in a subset of cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Dysregulation of apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased tumor burden seen with the progression of MGUS to MM is at least partially due to a dysregulation of apoptosis (programmed cell death). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=see_link&amp;anchor=H2#H2\">",
"     \"Apoptosis and autoimmune disease\", section on 'Molecular mechanisms of apoptosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This escape from apoptosis may be related to a number of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interleukin 6 (IL-6) is a cytokine that encourages the growth of plasma cells and enables them to evade apoptosis. Aberrant IL-6 expression is found in the majority of MM clones and results in a loss of spontaneous and drug-induced apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. This sustained survival signal is mediated through Mcl-1, which is an anti-apoptotic protein of the Bcl-2 family [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/75\">",
"       75",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Response to interleukin 6'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Overexpression of the anti-apoptotic protein Bcl-2 is seen in the majority of MM patients and in MM cell lines [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/76\">",
"       76",
"      </a>",
"      ]. High levels of Bcl-2 protein may contribute to the resistance of MM cells to apoptosis induced by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , IL-6 deprivation, or other drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/73,77\">",
"       73,77",
"      </a>",
"      ]. In an in vitro study, overexpression of Bcl-2 prevented apoptosis induced by IL-6 withdrawal in an IL-6-dependent MM cell line [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Approximately 65 percent of MM cases demonstrate hypermethylation of the promoter of death-associated protein (DAP) kinase [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/71\">",
"       71",
"      </a>",
"      ]. DAP-kinase regulates apoptosis induced by interferon alpha, and may affect overall prognosis.",
"     </li>",
"     <li>",
"      In normal B cells, binding of Fas to Fas ligand (FasL) induces apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/79\">",
"       79",
"      </a>",
"      ]. Point mutations in the Fas (CD95) gene can result in the absence of Fas protein in some MM clones resulting in prolonged cell survival [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast to normal B-cells, MM cells are subject to killing by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in vitro. As a result of its binding to TRAIL, osteoprotegerin (OPG) can inhibit the induction of apoptosis of myeloma cells generated by TRAIL [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Bone marrow microenvironment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous changes in the bone marrow microenvironment have been associated with the progression of MGUS to MM. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Induction of angiogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/82,83\">",
"       82,83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Suppression of cell-mediated immunity [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/84\">",
"       84",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Paracrine loops involving cytokines such as interleukin-6 and vascular endothelial growth factor (VEGF) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/85\">",
"       85",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Angiogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiogenesis may be a critical factor in the progression of MGUS to MM by providing an adequate tumor nutrient supply and by paracrine stimulation of tumor growth. The role of angiogenesis in disease progression is suggested by observations that demonstration of angiogenesis in cases of solitary plasmacytoma at the time of diagnosis predicts progression to myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/83\">",
"     83",
"    </a>",
"    ]. Further, there is a gradual increase in the degree of bone marrow angiogenesis along the disease spectrum from MGUS to smoldering myeloma (SMM) to symptomatic myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/82\">",
"     82",
"    </a>",
"    ]. In one study, approximately 60 percent of myeloma bone marrow plasma samples stimulated angiogenesis in an in vitro angiogenesis assay, compared with zero percent of SMM and 7 percent of MGUS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/86\">",
"     86",
"    </a>",
"    ]. Increased angiogenesis in MM is correlated with disease activity, bone marrow plasma cell involvement, and plasma cell proliferative capacity.",
"   </p>",
"   <p>",
"    The increased angiogenesis seen in MM may be related to the expression of pro-angiogenic cytokines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a loss of angiogenesis inhibitor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. As an example, an in vitro study of angiogenesis demonstrated that a significantly higher percentage of bone marrow plasma samples from patients with MGUS inhibited angiogenesis when compared with samples from patients with SMM or MM (63, 43, and 4 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pathobiology of end organ damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the clonal plasma cell population is created and progresses to MM, patients develop symptoms (eg, hypercalcemia, lytic bone lesions, renal dysfunction, and anemia) related to the infiltration of plasma cells into the bone or other organs or to kidney damage from excess light chains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Osteolytic bone lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteolytic bone lesions are the hallmark of MM. Although there are some data suggesting abnormalities in bone metabolism in MGUS, the presence of osteolytic bone lesions signals the onset of active malignancy. The pathogenesis of lytic bone lesions characteristic of MM is currently thought to be mediated by an imbalance between the activity of osteoclasts and osteoblasts. This imbalance is caused both by enhanced osteoclastic activity as well as (in contrast to other malignancies) a marked suppression of osteoblastic activity. As a result, MM bone lesions tend to be purely osteolytic and better visualized on plain radiographs compared with other bone metastases from solid tumors that tend to have an osteoblastic component and are better visualized on radionucleotide bone scans.",
"   </p>",
"   <p>",
"    Increased osteolytic activity is mediated by an increase in RANKL (receptor activator of nuclear factor kappa-B ligand) expression by osteoblasts (and possibly plasma cells) accompanied by a reduction in the level of its decoy receptor, osteoprotegerin (OPG) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. This leads to an increase in",
"    <span class=\"nowrap\">",
"     RANKL/OPG",
"    </span>",
"    ratio, which causes osteoclast activation and bone resorption. Increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha, CCL3), IL-3, and IL-6 produced by marrow stromal cells also contribute to the overactivity of osteoclasts. Finally, there is increased expression of stromal derived factor 1&alpha; (SDF-1alpha) by stromal cells and myeloma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/90\">",
"     90",
"    </a>",
"    ]. SDF-1alpha causes osteoclast activation by binding to CXCR4 on osteoclast precursors.",
"   </p>",
"   <p>",
"    In addition to osteoclast activation, there is active suppression of osteoblasts in myeloma. This is most likely related to increased levels of IL-3, IL-7 and dickkopf 1 (DKK1), which inhibit osteoblast differentiation in MM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/91\">",
"     91",
"    </a>",
"    ]. MM cells express DKK1, an inhibitor of Wnt signaling, and increased expression of DKK1 by these cells has been associated with presence of focal bone lesions in MM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/91\">",
"     91",
"    </a>",
"    ]. Increased IL-3 and IL-7 levels may also play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia appears to be a product of osteoclast activating factors such as lymphotoxin, interleukin-6, hepatocyte growth factor, and receptor activator of nuclear factor kappa B ligand (RANK ligand). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology of hypercalcemia\", section on 'Malignancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement in MM is usually the result of monoclonal immunoglobulin light chains. However, in rare occasions, monoclonal heavy chains or the entire immunoglobulins may be involved. Non-monoclonal protein-related renal injury may also occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=see_link\">",
"     \"Types of renal disease in multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the bone marrow in MM can result in anemia thought to be due to both the replacement of normal hematopoietic tissue by tumor (myelophthisis) and by the disruption of the bone marrow microenvironment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link&amp;anchor=H9#H9\">",
"     \"Hematologic consequences of malignancy: Anemia and bleeding\", section on 'Bone marrow replacement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relatively common occurrence of anemia in the setting of limited bone marrow infiltration suggests that MM-associated anemia is not entirely due to bone marrow replacement by malignant cells. Importantly, the bone marrow of patients with MM contains lower than normal numbers of hematopoietic stem and progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27977/abstract/92\">",
"     92",
"    </a>",
"    ]. This reduction in hematopoietic precursors appears to be at least partially due to changes in the bone marrow microenvironment. Elimination of myeloma cells and restoration of the normal bone marrow environment may result in repopulation with these precursors and reversal of the anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma (MM) is a malignant plasma cell disorder that accounts for approximately 10 percent of all hematologic malignancies and is thought to evolve from an asymptomatic pre-malignant stage of clonal plasma cell proliferation termed monoclonal gammopathy of undetermined significance (MGUS).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MM appears to arise from the malignant transformation of post-germinal center plasma cells. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cell of origin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of MM is complex and poorly understood. However, it is clear that there is a two-step model of progression (",
"      <a class=\"graphic graphic_figure graphicRef78232 \" href=\"UTD.htm?9/59/10166\">",
"       figure 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Establishment of a limited stage of clonal proliferation, clinically recognized as MGUS &mdash; This is associated with genetic changes (ie, either IgH translocations or hyperdiploidy), some of which are thought to be the product of an abnormal response to antigenic stimulation. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Establishment of MGUS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Progression of MGUS to MM &mdash; A second event, occurring at random rather than through cumulative damage, results in the accumulation of tumor cells and progression to MM. A number of progression events may act as this \"second hit.\" These include both genetic alterations and changes in the bone marrow microenvironment. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Progression of MGUS to MM'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms (eg, hypercalcemia, lytic bone lesions, renal dysfunction, and anemia) are related to the infiltration of plasma cells into the bone or other organs or to kidney damage from excess light chains. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Pathobiology of end organ damage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/2\">",
"      Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008; 68:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/3\">",
"      Corradini P, Boccadoro M, Voena C, Pileri A. Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. J Exp Med 1993; 178:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/4\">",
"      Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/5\">",
"      Pilarski LM, Jensen GS. Monoclonal circulating B cells in multiple myeloma. A continuously differentiating, possibly invasive, population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 1992; 6:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/6\">",
"      Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/7\">",
"      Landgren O, Kyle RA, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113:5412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/8\">",
"      Ichimaru M, Ishimaru T, Mikami M, Matsunaga M. Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: relationship to radiation dose absorbed by marrow. J Natl Cancer Inst 1982; 69:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/9\">",
"      Iwanaga M, Tagawa M, Tsukasaki K, et al. Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors. Blood 2009; 113:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/10\">",
"      Preston DL, Kusumi S, Tomonaga M, et al. Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 1994; 137:S68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/11\">",
"      LEWIS EB. LEUKEMIA, MULTIPLE MYELOMA, AND APLASTIC ANEMIA IN AMERICAN RADIOLOGISTS. Science 1963; 142:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/12\">",
"      Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am 1992; 6:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/13\">",
"      Kyle RA, Rajkumar SV. Epidemiology of the plasma-cell disorders. Best Pract Res Clin Haematol 2007; 20:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/14\">",
"      Zandecki M, La&iuml; JL, Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 1996; 94:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/15\">",
"      Sawyer JR, Lukacs JL, Thomas EL, et al. Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. Br J Haematol 2001; 112:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/16\">",
"      Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002; 99:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/17\">",
"      Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 2000; 96:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/18\">",
"      Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 2009; 27:4585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/19\">",
"      Fonseca R, Bergsagel PL, Drach J, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/20\">",
"      Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/21\">",
"      Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/22\">",
"      Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001; 20:5611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/23\">",
"      Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/24\">",
"      Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101:4569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/25\">",
"      Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002; 99:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/26\">",
"      Drach J, Angerler J, Schuster J, et al. Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 1995; 86:3915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/27\">",
"      Fonseca R, Aguayo P, Ahmann GJ, et al. Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes. Blood 1999; 94(Suppl1):663a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/28\">",
"      Rajkumar SV. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematology Am Soc Hematol Educ Program 2005; :340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/29\">",
"      Chng WJ, Van Wier SA, Ahmann GJ, et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005; 106:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/30\">",
"      Magrangeas F, Lod&eacute; L, Wuilleme S, et al. Genetic heterogeneity in multiple myeloma. Leukemia 2005; 19:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/31\">",
"      Kaufmann H, Ackermann J, Baldia C, et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004; 18:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/32\">",
"      Mantovani A, Garlanda C. Inflammation and multiple myeloma: the Toll connection. Leukemia 2006; 20:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/33\">",
"      Jego G, Bataille R, Geffroy-Luseau A, et al. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006; 20:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/34\">",
"      Bohnhorst J, Rasmussen T, Moen SH, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006; 20:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/35\">",
"      Van Damme J, Opdenakker G, Simpson RJ, et al. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med 1987; 165:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/36\">",
"      Xu FH, Sharma S, Gardner A, et al. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood 1998; 92:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/37\">",
"      Nordan RP, Mock BA, Neckers LM, Rudikoff S. The role of plasmacytoma growth factor in the in vitro responses of murine plasmacytoma cells. Ann N Y Acad Sci 1989; 557:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/38\">",
"      P&eacute;rez-Andr&eacute;s M, Almeida J, Mart&iacute;n-Ayuso M, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 2005; 19:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/39\">",
"      Rawstron AC, Fenton JA, Ashcroft J, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000; 96:3880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/40\">",
"      Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/41\">",
"      Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73:517.",
"     </a>",
"    </li>",
"    <li>",
"     Nilsson K, Jernberg H, Pettersson M. IL-6 as a growth factor for human myeloma cells: a short overview. In: Current topics of microbiology and immunology, Melchers F, Potter M (Eds), Springer-Verlag, Berlin 1990. Vol 166, p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/43\">",
"      Anderson KC, Jones RM, Morimoto C, et al. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/44\">",
"      Uchiyama H, Barut BA, Mohrbacher AF, et al. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993; 82:3712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/45\">",
"      Puthier D, Derenne S, Barill&eacute; S, et al. Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol 1999; 107:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/46\">",
"      Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/47\">",
"      Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/48\">",
"      Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/49\">",
"      Walker BA, Leone PE, Chiecchio L, et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood 2010; 116:e56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/50\">",
"      L&oacute;pez-Corral L, Guti&eacute;rrez NC, Vidriales MB, et al. The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells. Clin Cancer Res 2011; 17:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/51\">",
"      Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 2000; 97:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/52\">",
"      Avet-Loiseau H, Gerson F, Magrangeas F, et al. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. Blood 2001; 98:3082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/53\">",
"      Holien T, V&aring;tsveen TK, Hella H, et al. Addiction to c-MYC in multiple myeloma. Blood 2012; 120:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/54\">",
"      Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006; 108:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/55\">",
"      Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My&eacute;lome. Blood 2007; 109:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/56\">",
"      Drach J, Kaufmann H, Urbauer E, et al. The biology of multiple myeloma. J Cancer Res Clin Oncol 2000; 126:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/57\">",
"      Chang H, Yeung J, Qi C, Xu W. Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. Br J Haematol 2007; 138:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/58\">",
"      Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood 2008; 112:4235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/59\">",
"      Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 2009; 114:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/60\">",
"      Chang H, Sloan S, Li D, Keith Stewart A. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol 2004; 127:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/61\">",
"      Kalakonda N, Rothwell DG, Scarffe JH, Norton JD. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood 2001; 98:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/62\">",
"      Liu P, Leong T, Quam L, et al. Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996; 88:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/63\">",
"      Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007; 12:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/64\">",
"      Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/65\">",
"      Demchenko YN, Glebov OK, Zingone A, et al. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 2010; 115:3541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/66\">",
"      Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/67\">",
"      Kulkarni MS, Daggett JL, Bender TP, et al. Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis. Leukemia 2002; 16:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/68\">",
"      Tasaka T, Berenson J, Vescio R, et al. Analysis of the p16INK4A, p15INK4B and p18INK4C genes in multiple myeloma. Br J Haematol 1997; 96:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/69\">",
"      Mateos MV, Garc&iacute;a-Sanz R, L&oacute;pez-P&eacute;rez R, et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002; 118:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/70\">",
"      Guillerm G, Gyan E, Wolowiec D, et al. p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 2001; 98:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/71\">",
"      Ng MH, Chung YF, Lo KW, et al. Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 1997; 89:2500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/72\">",
"      Tasaka T, Asou H, Munker R, et al. Methylation of the p16INK4A gene in multiple myeloma. Br J Haematol 1998; 101:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/73\">",
"      Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/74\">",
"      Lichtenstein A, Tu Y, Fady C, et al. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995; 162:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/75\">",
"      Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/76\">",
"      Ong F, van Nieuwkoop JA, de Groot-Swings GM, et al. Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia 1995; 9:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/77\">",
"      Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 1995; 55:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/78\">",
"      Gauthier ER, Pich&eacute; L, Lemieux G, Lemieux R. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells. Cancer Res 1996; 56:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/79\">",
"      Silvestris F, Tucci M, Cafforio P, Dammacco F. Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. Blood 2001; 97:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/80\">",
"      Landowski TH, Qu N, Buyuksal I, et al. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997; 90:4266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/81\">",
"      Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003; 63:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/82\">",
"      Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/83\">",
"      Kumar S, Fonseca R, Dispenzieri A, et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003; 101:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/84\">",
"      Galea HR, Cogn&eacute; M. GM-CSF and IL-12 production by malignant plasma cells promotes cell-mediated immune responses against monoclonal Ig determinants in a light chain myeloma model. Clin Exp Immunol 2002; 129:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/85\">",
"      Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003; 88:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/86\">",
"      Kumar S, Witzig TE, Timm M, et al. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 2004; 104:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/87\">",
"      Kumar S, Witzig TE, Timm M, et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/88\">",
"      Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 2002; 17:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/89\">",
"      Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/90\">",
"      Sezer O. Myeloma bone disease: recent advances in biology, diagnosis, and treatment. Oncologist 2009; 14:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/91\">",
"      Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27977/abstract/92\">",
"      Bruns I, Cadeddu RP, Brueckmann I, et al. Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. Blood 2012; 120:2620.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6660 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27977=[""].join("\n");
var outline_f27_20_27977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CELL OF ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ESTABLISHMENT OF MGUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Immunoglobulin heavy chain translocations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Hyperdiploidy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Aberrant response to antigenic stimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Toll like receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Response to interleukin 6",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGRESSION OF MGUS TO MM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Secondary cytogenetic changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Secondary IgH translocations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Deletion of 17p13",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ras mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Activation of NF kappa B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cell cycle dysregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Dysregulation of apoptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Bone marrow microenvironment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Angiogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pathobiology of end organ damage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Osteolytic bone lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6660\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6660|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/59/10166\" title=\"figure 1\">",
"      Pathogenesis MM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6660|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/26/40363\" title=\"table 1\">",
"      MGUS cytogenic changes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/38/5735?source=related_link\">",
"      Apoptosis and autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4041?source=related_link\">",
"      Clinical course and management of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2791?source=related_link\">",
"      Pathobiology of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/1/44054?source=related_link\">",
"      Pathobiology of mantle cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27400?source=related_link\">",
"      Types of renal disease in multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_20_27978="Preeclampsia: Clinical features and diagnosis";
var content_f27_20_27978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Preeclampsia: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27978/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27978/contributors\">",
"     Phyllis August, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27978/contributors\">",
"     Baha M Sibai, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27978/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27978/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/20/27978/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/20/27978/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/20/27978/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia is a multi-system disorder characterized by hypertension and proteinuria in the last half of pregnancy. Although most affected pregnancies deliver at term or near term with good maternal and fetal outcomes, these pregnancies are at increased risk for maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal mortality or serious morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14938176\">",
"    <span class=\"h1\">",
"     DEFINITIONS OF PREGNANCY-RELATED HYPERTENSIVE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major hypertensive disorders related to pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Preeclampsia",
"      </strong>",
"      &mdash; Preeclampsia refers to the new onset of hypertension and proteinuria (",
"      <a class=\"graphic graphic_table graphicRef79977 \" href=\"UTD.htm?4/31/4603\">",
"       table 1",
"      </a>",
"      ) after 20 weeks of gestation in a previously normotensive woman. Clinically, preeclampsia can be classified as &lsquo;severe&rsquo; when severe hypertension, severe proteinuria, or other",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"      of end-organ injury are present (",
"      <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. In the absence of any of these findings, preeclampsia can be classified as &lsquo;mild.&rsquo; In this commonly used system, there is no &lsquo;moderate&rsquo; classification.",
"      <br/>",
"      <br/>",
"      <strong>",
"       Eclampsia",
"      </strong>",
"      refers to the development of grand mal seizures in a woman with preeclampsia, in the absence of other neurologic conditions that could account for the seizure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link\">",
"       \"Eclampsia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      <strong>",
"       HELLP",
"      </strong>",
"      syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) probably represents a severe form of preeclampsia, but this relationship remains controversial; HELLP may be an independent disorder. As many as 15 to 20 percent of affected patients do not have concurrent hypertension or proteinuria, leading some experts to believe that HELLP syndrome is a separate disorder from preeclampsia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      .)",
"      <br/>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Chronic/preexisting",
"       </strong>",
"      </span>",
"      hypertension",
"      &mdash;",
"      <span class=\"nowrap\">",
"       Chronic/preexisting",
"      </span>",
"      hypertension is defined as systolic pressure &ge;140 mmHg",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic pressure &ge;90 mmHg that antedates pregnancy or is present before the 20th week of pregnancy (on at least two occasions) or persists longer than 12 weeks postpartum. It can be primary (essential hypertension) or secondary to a variety of medical disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=see_link\">",
"       \"Overview of hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Preeclampsia superimposed upon",
"       <span class=\"nowrap\">",
"        chronic/preexisting",
"       </span>",
"       hypertension",
"      </strong>",
"      &mdash; Superimposed preeclampsia is defined by the new onset of proteinuria after 20 weeks of gestation in a woman with",
"      <span class=\"nowrap\">",
"       chronic/preexisting",
"      </span>",
"      hypertension. For women with",
"      <span class=\"nowrap\">",
"       chronic/preexisting",
"      </span>",
"      hypertension who have proteinuria prior to or in early pregnancy, superimposed preeclampsia is defined by worsening or resistant hypertension (especially acutely) in the last half of pregnancy or development of",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"      of severe preeclampsia (",
"      <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Gestational hypertension",
"      </strong>",
"      &mdash; During pregnancy, gestational hypertension refers to hypertension without proteinuria or other",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"      of preeclampsia that develops after 20 weeks of gestation (",
"      <a class=\"graphic graphic_table graphicRef56709 \" href=\"UTD.htm?0/37/603\">",
"       table 3",
"      </a>",
"      ). It should resolve by 12 weeks postpartum. If hypertension persists beyond 12 weeks postpartum, the diagnosis is revised to",
"      <span class=\"nowrap\">",
"       chronic/preexisting",
"      </span>",
"      hypertension that was masked by the physiologic decrease in blood pressure that occurs in early pregnancy. If hypertension resolves postpartum, the diagnosis is revised to transient hypertension of pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=see_link\">",
"       \"Gestational hypertension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia occurs in up to 7.5 percent of pregnancies worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Variations in incidence reflect, at least in part, differences in the maternal age distribution and proportion of primiparous women among populations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1564260\">",
"    <span class=\"h1\">",
"     BURDEN OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with preeclampsia are at an increased risk for life-threatening events, including placental abruption, acute renal failure, cerebral hemorrhage, hepatic failure or rupture, pulmonary edema, disseminated intravascular coagulation, and progression to eclampsia. Worldwide, 10 to 15 percent of direct maternal deaths (ie, resulting from obstetric complications of pregnancy) are associated with",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/8\">",
"     8",
"    </a>",
"    ]. In the United States,",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia",
"    </span>",
"    is one of four leading causes of maternal death, along with hemorrhage, cardiovascular conditions, and thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. There is approximately one maternal death due to preeclampsia-eclampsia per 100,000 live births, with a case-fatality rate of 6.4 deaths per 10,000 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In the Netherlands between 1993 and 2005, preeclampsia was the most common cause of maternal death, with 3.5 maternal deaths per 100,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40888?source=see_link\">",
"     \"Overview of maternal mortality\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Morbidity and mortality are also increased for the",
"    <span class=\"nowrap\">",
"     fetus/neonate",
"    </span>",
"    because of the greater risk of restricted fetal growth and preterm birth in affected pregnancies.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for preeclampsia are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef61266 \" href=\"UTD.htm?43/39/44667\">",
"     table 4",
"    </a>",
"    ). The magnitude of risk depends upon the specific factor and is described below for selected risk factors evaluated in a systematic review of controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A past history of preeclampsia increases the risk of developing preeclampsia in a subsequent pregnancy seven-fold compared to women without this history (RR 7.19, 95% CI 5.85-8.83) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"       15",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The severity of preeclampsia strongly impacts this risk. Women with severe second trimester preeclampsia are at greatest risk of developing preeclampsia in a subsequent pregnancy: rates of 25 to 65 percent have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/16-19\">",
"       16-19",
"      </a>",
"      ]. By comparison, women with mild preeclampsia in their first pregnancy develop preeclampsia in 5 to 7 percent of second pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. Women who had a normotensive first delivery develop preeclampsia in less than 1 percent of second pregnancies.",
"     </li>",
"     <li>",
"      First pregnancy (nulliparity) (RR 2.91, 95% CI 1.28-6.61) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"       15",
"      </a>",
"      ]. It is unclear why the primigravid state is a significant predisposing factor. One theory is that these women may have had limited recent exposure to paternal antigens, which may play a role in the pathogenesis of the disease.",
"     </li>",
"     <li>",
"      A family history of preeclampsia in a first degree relative (RR 2.90, 95% CI 1.70-4.93) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"       15",
"      </a>",
"      ], suggesting a heritable mechanism in some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. The father of the baby may contribute to the increased risk, as the paternal contribution to fetal genes may have a role in defective placentation and subsequent preeclampsia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link&amp;anchor=H8#H8\">",
"       \"Pathogenesis of preeclampsia\", section on 'Genetic factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preexisting medical conditions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pregestational diabetes (RR 3.56, 95% CI 2.54-4.99) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"       15",
"      </a>",
"      ], an effect that is probably related to a variety of factors, such as underlying renal or vascular disease, high plasma insulin",
"      <span class=\"nowrap\">",
"       levels/insulin",
"      </span>",
"      resistance, and abnormal lipid metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=see_link\">",
"       \"Pregnancy risks in women with type 1 and type 2 diabetes mellitus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=see_link\">",
"       \"Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blood pressure",
"      <span class=\"nowrap\">",
"       &ge;130/80",
"      </span>",
"      mm Hg at the first prenatal visit (RR 1.38-2.37) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"       15",
"      </a>",
"      ]. The risk of superimposed preeclampsia is highest in women with diastolic blood pressure &ge;110 mm Hg (RR 5.2) and &ge;100 mm Hg (RR 3.2) before 20 weeks of gestation.",
"     </li>",
"     <li>",
"      Antiphospholipid antibodies (RR 9.72, 95% CI 4.34-21.75) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"       \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Body mass index &ge;26.1 (RR 2.47, 95% CI 1.66-3.67) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link&amp;anchor=H11#H11\">",
"       \"The impact of obesity on fertility and pregnancy\", section on 'Pregnancy associated hypertension'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twin pregnancies (RR 2.93, 95% 2.04-4.21) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"       15",
"      </a>",
"      ]. The risk increases with increasing number of fetuses in multiple gestations: triplet pregnancy triples the risk of preeclampsia compared with twin pregnancy.",
"     </li>",
"     <li>",
"      Advanced maternal age (maternal age &ge;40 RR 1.96, 95% CI 1.34-2.87 for multiparas and RR 1.68, 95% CI 1.23-2.29 for primiparas) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"       15",
"      </a>",
"      ]. Older women tend to have additional risk factors, such as diabetes mellitus and chronic hypertension. Whether adolescents are at higher risk of preeclampsia is more controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/25\">",
"       25",
"      </a>",
"      ]; a systematic review did not find an association [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"       \"Effect of advanced age on fertility and pregnancy in women\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, women who smoke cigarettes have a",
"    <strong>",
"     lower",
"    </strong>",
"    risk of preeclampsia than nonsmokers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link&amp;anchor=H18#H18\">",
"     \"Smoking and pregnancy\", section on 'Preeclampsia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14937496\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of preeclampsia likely involves both maternal and",
"    <span class=\"nowrap\">",
"     fetal/placental",
"    </span>",
"    factors. Abnormalities in the development of the placental vasculature early in pregnancy, weeks to months before development of clinical manifestations of the disease, are well-documented [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. These abnormalities can result in placental underperfusion, and possibly hypoxia and ischemia. Observational data support the hypothesis that placental underperfusion, hypoxia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemia may lead to release of circulating antiangiogenic factors (soluble fms&ndash;like tyrosine kinase [sFlt-1], soluble endoglin [sEng]) and other substances that can cause widespread maternal systemic endothelial dysfunction (increased vascular permeability, vasoconstriction, activation of coagulation system, microangiopathic hemolysis), resulting in hypertension, proteinuria, and the other clinical manifestations of preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/28\">",
"     28",
"    </a>",
"    ]. The severity of the disease is influenced primarily by maternal and pregnancy-specific factors, but paternal and environmental factors may also play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link\">",
"     \"Pathogenesis of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14938198\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The new development of hypertension and proteinuria after 20 weeks of gestation is usually due to preeclampsia, particularly in a nulliparous woman. In most women, these findings first become apparent after 34 weeks of gestation, including when the woman is in labor (ie, &ldquo;late onset preeclampsia&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In about 10 percent of women, hypertension and proteinuria develop before 34 weeks of gestation (ie, &ldquo;early onset preeclampsia&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/30\">",
"     30",
"    </a>",
"    ], and in about 5 percent, preeclampsia is first recognized postpartum (ie, &ldquo;postpartum preeclampsia&rdquo;), usually within 48 hours of delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of maternal hypertension and proteinuria, and the",
"    <span class=\"nowrap\">",
"     presence/absence",
"    </span>",
"    of other clinical manifestations of the disease are highly variable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/35\">",
"     35",
"    </a>",
"    ]. Most patients have only mild hypertension",
"    <span class=\"nowrap\">",
"     (&ge;140/90",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     &lt;160/110",
"    </span>",
"    mm Hg) and mild proteinuria (&lt;5 grams in 24 hours), usually accompanied by peripheral edema. About 25 percent develop one or more of the following nonspecific findings:",
"   </p>",
"   <p>",
"    Signs and symptoms",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe hypertension (systolic blood pressure &ge;160 mm Hg or diastolic &ge;110 mm Hg on two occasions at least six hours apart)",
"     </li>",
"     <li>",
"      Persistent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe headache,",
"     </li>",
"     <li>",
"      Visual abnormalities (scotomata, photophobia, blurred vision, or temporary blindness [rare])",
"     </li>",
"     <li>",
"      Upper abdominal or epigastric pain",
"     </li>",
"     <li>",
"      Nausea, vomiting",
"     </li>",
"     <li>",
"      Oliguria",
"     </li>",
"     <li>",
"      Dyspnea, retrosternal chest pain",
"     </li>",
"     <li>",
"      Fetal growth restriction",
"     </li>",
"     <li>",
"      Oligohydramnios",
"     </li>",
"     <li>",
"      Altered mental status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory abnormalities",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hemoconcentration",
"     </li>",
"     <li>",
"      Microangiopathic hemolytic anemia (abnormal peripheral smear, elevated bilirubin, or low serum haptoglobin levels",
"      <span class=\"nowrap\">",
"       U/L)",
"      </span>",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"      <span class=\"nowrap\">",
"       (&lt;100,000/microL)",
"      </span>",
"     </li>",
"     <li>",
"      Elevated serum creatinine concentration (&gt;1.3",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"     </li>",
"     <li>",
"      Elevated liver enzymes (twice the upper limit of normal)",
"     </li>",
"     <li>",
"      Severe proteinuria (&ge;5 grams in 24 hours)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3257289\">",
"    <span class=\"h3\">",
"     Atypical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical presentations include any of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Onset of",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"      at &lt;20 weeks of gestation",
"     </li>",
"     <li>",
"      Hypertension or proteinuria (but not both) with or without characteristic signs and symptoms of severe preeclampsia",
"     </li>",
"     <li>",
"      Delayed postpartum onset or exacerbation of disease (&gt;2 days postpartum)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356055\">",
"    <span class=\"h4\">",
"     Onset &lt;20 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia prior to 20 weeks of gestation is usually associated with a complete or partial molar pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    .) Rarely, characteristic signs and symptoms before 20 weeks have been attributed to severe preeclampsia after other disorders with similar findings (eg, lupus nephritis, thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, antiphospholipid syndrome, acute fatty liver of pregnancy) were excluded. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H356069\">",
"    <span class=\"h4\">",
"     Hypertension or proteinuria (not both)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension or proteinuria (but not both) with characteristic signs and symptoms of severe preeclampsia is uncommon, but may be observed in 15 percent of patients with HELLP syndrome and in some patients with eclampsia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link&amp;anchor=H25#H25\">",
"     \"Eclampsia\", section on 'Can eclampsia be predicted?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with hypertension or proteinuria (but not both) may go on to develop preeclampsia. No prospective studies have been performed in pregnant women with isolated gestational proteinuria to determine their risk of developing preeclampsia later in pregnancy. Between 15 and 25 percent of women with gestational hypertension subsequently develop preeclampsia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=see_link&amp;anchor=H3#H3\">",
"     \"Gestational hypertension\", section on 'Risk of progression to preeclampsia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10750197\">",
"    <span class=\"h4\">",
"     Delayed postpartum onset or exacerbation of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed postpartum preeclampsia can be defined as signs and symptoms of the disease leading to readmission more than two days but less than six weeks after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/34\">",
"     34",
"    </a>",
"    ], although various other definitions have been used. In a retrospective cohort study including 152 patients with delayed postpartum preeclampsia, 63.2 percent had no antecedent diagnosis of hypertensive disease in the current pregnancy, whereas 18.4 percent had preeclampsia, 9.2 percent had chronic hypertension, 4.6 percent had gestational hypertension, and 4.6 percent had preeclampsia superimposed on chronic hypertension during the peripartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/34\">",
"     34",
"    </a>",
"    ]. Of these patients, 14.5 percent developed postpartum eclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1566744\">",
"    <span class=\"h2\">",
"     Course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women have only mild hypertension and mild proteinuria that gradually worsen until delivery. In about 25 percent of women, especially those with early onset preeclampsia, hypertension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria reach a severe level",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs and symptoms of end-organ damage become apparent over a period of days to weeks (",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/37\">",
"     37",
"    </a>",
"    ]. Two percent of these women develop eclampsia.",
"   </p>",
"   <p>",
"    Severe preeclampsia can be associated with serious maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal sequelae (eg, abruptio placentae; liver hematoma or rupture; disseminated intravascular coagulation; stroke; need for mechanical ventilation, invasive hemodynamic monitoring, transfusion, or dialysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. It is important to note that severe sequelae can occur in women with mild hypertension and mild proteinuria who have clinical evidence of significant end-organ dysfunction. Chest pain, dyspnea, low oxygen saturation, low platelet count, and elevated creatinine and aspartate transaminase concentrations appear to be particularly predictive of adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/40\">",
"     40",
"    </a>",
"    ]. &nbsp;",
"    <br/>",
"   </p>",
"   <p>",
"    Delivery of the placenta always results in complete resolution of signs and symptoms of the disease. Typically, mobilization of third-space fluid and diuresis begin within 48 hours of delivery. Hypertension may worsen during the first, and occasionally the second, postpartum week, but normalizes in most women within four weeks postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/41\">",
"     41",
"    </a>",
"    ]. Rarely, hypertension persists beyond three months. Proteinuria usually begins to improve within a few days, however, in women with several grams of protein excretion, complete resolution may take weeks to months; a prolonged time to complete resolution is more likely with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/42\">",
"     42",
"    </a>",
"    ]. Delayed postpartum onset or exacerbation of disease is atypical (see",
"    <a class=\"local\" href=\"#H10750197\">",
"     'Delayed postpartum onset or exacerbation of disease'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14938205\">",
"    <span class=\"h2\">",
"     Clinical features and pathophysiology by organ system",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14938426\">",
"    <span class=\"h3\">",
"     Cardiopulmonary",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is generally the earliest clinical finding of preeclampsia and is the most common clinical clue to the presence of the disease. The blood pressure usually rises gradually, reaching the hypertensive range",
"    <span class=\"nowrap\">",
"     (&ge;140/90",
"    </span>",
"    mmHg) sometime in the third trimester, often after the 37th week of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/30\">",
"     30",
"    </a>",
"    ]. However, in some women, hypertension develops rapidly or before 34 weeks of gestation or postpartum. A systolic blood pressure of &ge;160 mm Hg or diastolic blood pressure of &ge;110 mm Hg on two occasions at least six hours apart upstages preeclampsia from mild to severe [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14939004\">",
"    <span class=\"h4\">",
"     Intravascular volume and edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravascular volume is reduced in preeclampsia. There is no evidence of underfilling of the arterial circulation; rather, the reduced volume appears to be a consequence of vasoconstriction from enhanced responses to vasoactive substances. This issue has not been conclusively resolved.",
"   </p>",
"   <p>",
"    Edema in preeclampsia may be due to capillary leaking or represent \"overfill\" edema. Many pregnant women have edema, whether or not they have preeclampsia. However, sudden and rapid weight gain (eg, &gt;5",
"    <span class=\"nowrap\">",
"     pounds/week)",
"    </span>",
"    and facial edema are more common in women who develop preeclampsia, thus, these findings warrant evaluation for other clinical manifestations of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14938568\">",
"    <span class=\"h4\">",
"     Cardiac function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia does not affect the myocardium directly, but the heart responds to physiological changes induced by preeclampsia. Left ventricular ejection fraction usually remains within normal limits [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/43\">",
"     43",
"    </a>",
"    ], but reductions in longitudinal, circumferential, and radial systolic strain have been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/44\">",
"     44",
"    </a>",
"    ]. The decrement in left ventricular performance in women with preeclampsia has been attributed to a physiologic response to increased afterload [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/43-45\">",
"     43-45",
"    </a>",
"    ], but other factors may play a role since systolic strain was depressed in preeclamptic patients compared to pregnant women with nonproteinuric hypertension with similar resting blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/44\">",
"     44",
"    </a>",
"    ]. The high afterload in preeclampsia is associated with elevated cardiac filling pressures, reflected by four-fold higher concentrations of natriuretic peptides in women with preeclampsia compared to pregnant women who are normotensive or have chronic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe preeclampsia can be associated with a highly variable hemodynamic profile [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. A small subgroup of women with severe preeclampsia develops myocardial damage or global diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/50\">",
"     50",
"    </a>",
"    ]. Troponin I levels should be obtained when clinically indicated, such as when the patient complains of chest pain suggestive of myocardial ischemia or new electrocardiogram changes are observed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Preeclampsia is not associated with elevated troponin levels in the absence of cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14938575\">",
"    <span class=\"h4\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of pulmonary edema upstages the diagnosis from mild to severe preeclampsia. The etiology of pulmonary edema in preeclampsia is multifactorial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Excessive elevation in pulmonary vascular hydrostatic pressure compared with plasma oncotic pressure may produce pulmonary edema in some women, particularly in the postpartum period. However, not all preeclamptic patients with pulmonary edema demonstrate this phenomenon. Other causes of pulmonary edema are capillary leak, left heart failure, and iatrogenic volume overload.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14938441\">",
"    <span class=\"h3\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidney is the organ most likely to manifest endothelial injury related to preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteinuria in preeclampsia is defined as &ge;0.3 grams protein in a 24-hour urine specimen or persistent 1+ (30",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    on dipstick or a random protein:creatinine ratio &gt;30",
"    <span class=\"nowrap\">",
"     mg/mmol.",
"    </span>",
"    The presence of &ge;5 grams of protein in a 24-hour urine collection upstages preeclampsia from mild to severe. Although proteinuria in women with preeclampsia is most often in the mild to moderate range (&lt;5 g), preeclampsia remains the most common cause of severe proteinuria in pregnant women; levels of proteinuria &gt;10",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    may be seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23544?source=see_link\">",
"     \"Evaluation of proteinuria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary protein excretion may be a late finding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], but generally increases as preeclampsia progresses. It is due, in part, to impaired integrity of the glomerular barrier and altered tubular handling of filtered proteins (hypofiltration) leading to increased protein excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/60\">",
"     60",
"    </a>",
"    ]. Both size and charge selectivity of the glomerular barrier are affected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/61\">",
"     61",
"    </a>",
"    ]. Using special studies, podocyturia (urinary excretion of podocytes) has been observed in patients with preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/62\">",
"     62",
"    </a>",
"    ]. Urinary shedding of podocytes may indicate podocyte loss from the glomerulus, which may lead to a disruption of the glomerular filtration barrier and consequent proteinuria. Deficient vascular endothelial growth factor (VEGF) signaling appears to account, at least in part, for these effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis of preeclampsia\", section on 'Pathogenesis of systemic endothelial dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular filtration rate (GFR) decreases by 30 to 40 percent in preeclampsia compared to pregnant normotensive controls; renal plasma flow also decreases, but to a lesser degree. The plasma creatinine concentration is generally normal or only slightly elevated (1.0 to 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [88 to 133",
"    <span class=\"nowrap\">",
"     micromol/L]).",
"    </span>",
"    A rising creatinine and oliguria, ie, urine output &lt;500",
"    <span class=\"nowrap\">",
"     mL/24",
"    </span>",
"    hours, indicates severe disease and results from renal vasoconstriction and sodium retention due to reduced plasma volume and systemic vasoconstriction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=see_link&amp;anchor=H3#H3\">",
"     \"Acute kidney injury (acute renal failure) in pregnancy\", section on 'Preeclampsia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperuricemia and hypocalciuria are also observed; the mechanisms for these changes are not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/60,63,64\">",
"     60,63,64",
"    </a>",
"    ]. The rise in serum uric acid concentration is thought to reflect increased proximal sodium resorption and, secondarily, urate reabsorption induced by renal ischemia. Other possible mechanisms for hyperuricemia in preeclampsia include underlying metabolic syndrome, tissue damage, oxidative stress, and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although hyperuricemia is associated with preeclampsia, serum uric acid level is a poor predictor of development of the disease or maternal and fetal complications in women with preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. However, an elevated uric acid level (&gt;6.0",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    at the time of diagnosis appears to identify women at risk of delivery within seven days, whereas a low uric acid level (&le;4.0",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    is associated with a prolonged latency period [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H942170\">",
"    <span class=\"h4\">",
"     Urine sediment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine sediment is typically benign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Renal histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renal histologic changes described in women with preeclampsia who have had kidney biopsies, and in autopsy specimens obtained from women who died of eclampsia, are termed &lsquo;glomerular endotheliosis.&rsquo; Light and electron microscopy of glomerular endotheliosis show the following (",
"    <a class=\"graphic graphic_picture graphicRef78879 graphicRef59970 graphicRef68634 \" href=\"UTD.htm?41/36/42570\">",
"     picture 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Endothelial cell swelling",
"     </li>",
"     <li>",
"      Loss of fenestrations",
"     </li>",
"     <li>",
"      Occlusion of capillary lumens",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Foot process effacement is not a prominent feature, despite marked proteinuria.",
"   </p>",
"   <p>",
"    Glomerular endotheliosis shares histologic features with non-preeclamptic thrombotic microangiopathies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/69\">",
"     69",
"    </a>",
"    ], except thrombi are rare in preeclampsia (although fibrin deposition may be observed by immunofluorescence microscopy). Rarely, it may be present without proteinuria and in nonpregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hematologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common coagulation abnormality in preeclampsia is thrombocytopenia. Microangiopathic endothelial injury and activation result in formation of platelet and fibrin thrombi in the microvasculature. Accelerated platelet consumption leads to thrombocytopenia; immune mechanisms may also play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/72\">",
"     72",
"    </a>",
"    ]. A platelet count less than",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    upstages preeclampsia from mild to severe.",
"   </p>",
"   <p>",
"    The prothrombin time, partial thromboplastin time, and fibrinogen concentration are not affected unless there are additional complications, such as abruptio placentae or severe liver dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microangiopathic hemolysis may also occur and is detected by examination of a blood smear for schistocytes and helmet cells (",
"    <a class=\"graphic graphic_picture graphicRef70851 graphicRef50715 \" href=\"UTD.htm?34/52/35657\">",
"     picture 2A-B",
"    </a>",
"    ) or elevation in the serum lactate dehydrogenase concentration. Hemoconcentration may result from reduction of plasma volume from capillary leaking. Hemolysis is associated with a low hematocrit, while hemoconcentration is associated with a high hematocrit; when both hemolysis and reduced plasma volume are present, the effects on hematocrit may negate each other, resulting in a normal value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link\">",
"     \"Thrombocytopenia in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17832?source=see_link\">",
"     \"Abnormalities of coagulation and platelet function in preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The white blood cell count may be slightly higher due to neutrophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hepatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periportal and sinusoidal fibrin deposition and microvesicular fat deposition are histologic findings observed in the livers of preeclamptic women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Reduced hepatic blood flow can lead to ischemia and periportal hemorrhage. The clinical manifestations of hepatic dysfunction include right upper quadrant or epigastric pain, elevated transaminase levels, coagulopathy, and, in the most severe cases, subcapsular hemorrhage or hepatic rupture. These hepatic changes upstage the preeclampsia from mild to severe. Nausea and vomiting may occur.",
"   </p>",
"   <p>",
"    Epigastric pain is one of the cardinal symptoms of severe preeclampsia. A review of this nonspecific symptom revealed that it is typically experienced as a severe constant pain that begins at night, usually maximal in the low retrosternum or epigastrium, but may radiate to the right hypochondrium or back [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/77\">",
"     77",
"    </a>",
"    ]. The pain is thought to be due to stretching of Glisson&rsquo;s capsule due to hepatic swelling or bleeding. It may be the only symptom on presentation, thus a high index of suspicion is important to make the diagnosis of preeclampsia rather than gastroesophageal reflux, which is common in pregnant women, especially at night. The liver may be tender to palpation.",
"   </p>",
"   <p>",
"    Rarely, transient diabetes insipidus has been reported in preeclampsia with hepatic dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link&amp;anchor=H40375199#H40375199\">",
"     \"Renal and urinary tract physiology in normal pregnancy\", section on 'DI associated with hepatic dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute pancreatitis is an even rarer complication of severe preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Central nervous system and eye",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system manifestations of preeclampsia include headache, visual symptoms, and generalized hyperreflexia; sustained ankle clonus may be present.",
"   </p>",
"   <p>",
"    Headache in preeclampsia may be temporal, frontal, occipital, or diffuse [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. It is usually a",
"    <span class=\"nowrap\">",
"     throbbing/pounding",
"    </span>",
"    pain, but may be piercing pain. Although not pathognomonic, a feature that suggests preeclampsia-related headache rather than another type of headache is that it persists despite administration of over-the-counter analgesics and it may become severe (ie, incapacitating, \"the worst headache of my life\").",
"   </p>",
"   <p>",
"    Visual symptoms are caused, at least in part, by constriction of retinal arteries. Symptoms include blurred vision, flashing lights (photopsia), and scotomata (dark areas or gaps in the visual field) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/81-83\">",
"     81-83",
"    </a>",
"    ]. Diplopia or amaurosis fugax (blindness in one eye) may also occur. Cortical blindness is rare and typically transient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/84\">",
"     84",
"    </a>",
"    ]. Blindness related to retinal pathology, such as retinal artery or venous thrombosis, retinal detachment, optic nerve damage, retinal artery spasm, and retinal ischemia, may be permanent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures in a preeclamptic woman signify a change in diagnosis to eclampsia. One in 400 mildly preeclamptic and 1 in 50 severely preeclamptic women develop eclamptic seizures.",
"   </p>",
"   <p>",
"    Histopathologic correlates include hemorrhage, petechiae, cerebral edema, vasculopathy, ischemic brain damage, microinfarcts, and fibrinoid necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cerebrovascular manifestations of severe preeclampsia are poorly understood. Cerebral edema and",
"    <span class=\"nowrap\">",
"     ischemic/hemorrhagic",
"    </span>",
"    changes in the posterior hemispheres observed on computed tomography and magnetic resonance imaging help to explain, but do not fully account for, the clinical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. These findings may result from vasospasm of the cerebral vasculature in response to severe hypertension or may result from loss of cerebrovascular autoregulation leading to areas of both vasoconstriction and forced vasodilation and thus represent a form of posterior reversible leukoencephalopathy syndrome (PRES) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. PRES is typically associated with severe hypertension, but can occur with rapid increases in blood pressure in patients with endothelial damage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=see_link\">",
"     \"Reversible posterior leukoencephalopathy syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=see_link&amp;anchor=H5#H5\">",
"     \"Eclampsia\", section on 'Clinical manifestations and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stroke leading to death or disability is the most serious complication of severe",
"    <span class=\"nowrap\">",
"     preeclampsia/eclampsia,",
"    </span>",
"    but is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Fetus and placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fetal consequences of chronic placental hypoperfusion are fetal growth restriction and oligohydramnios. Fetal growth restriction upstages preeclampsia from mild to severe.",
"   </p>",
"   <p>",
"    Severe and early onset preeclampsia result in the greatest decrements in birth weight compared to normotensive pregnancies, 12 and 23 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/93\">",
"     93",
"    </a>",
"    ]. By comparison, late onset preeclampsia can be associated with higher than average birth weight, possibly related to greater placental perfusion due to elevated cardiac output sometimes observed with late onset disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/94-98\">",
"     94-98",
"    </a>",
"    ]. However, this association may also be the result of confounders associated with both preeclampsia and birth of large for gestational age infants (eg, obesity, impaired glucose tolerance) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/99\">",
"     99",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Indicated preterm delivery is a secondary result of fetal or maternal complications. Preeclampsia does not appear to accelerate fetal maturation, as once believed. The frequency of neonatal morbidities such as respiratory distress, intraventricular hemorrhage, and necrotizing enterocolitis is similar in infants of preeclamptic women and age-matched nonhypertensive controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abruptio placenta is infrequent (less than 1 percent) in women with mild preeclampsia, but has been reported in 3 percent of those with severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=see_link\">",
"     \"Placental abruption: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Impaired placentation can lead to increased impedance to flow in the uterine arteries, manifested by elevation of the pulsatility index accompanied by uterine artery notching on uterine artery Doppler velocimetry. However, this finding is neither sensitive nor specific for preeclampsia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11480?source=see_link&amp;anchor=H7#H7\">",
"     \"Prediction of preeclampsia\", section on 'Uterine artery Doppler velocimetry'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased resistance in the placental vasculature is also reflected by rising Doppler indices of the umbilical artery. Absent and reversed end diastolic flow are the most severe abnormalities and associated with a poor perinatal outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=see_link\">",
"     \"Doppler ultrasound of the umbilical artery for fetal surveillance\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Placental histology is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=see_link&amp;anchor=H22#H22\">",
"     \"Histopathology of placental disorders\", section on 'Placental \"underperfusion\"'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal hydrops (nonimmune or immune) can result in maternal symptoms identical to those seen in typical preeclampsia. This disorder is called mirror or Ballantyne syndrome and resolves without delivery if hydrops resolves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H6#H6\">",
"     \"Nonimmune hydrops fetalis\", section on 'Mirror syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;International guidelines generally agree that the diagnosis of preeclampsia should be made in a previously normotensive woman with new onset of hypertension and proteinuria after 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/4,5,74,102,103\">",
"     4,5,74,102,103",
"    </a>",
"    ]. Criteria for diagnosis are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systolic blood pressure &ge;140 mmHg or diastolic blood pressure &ge;90 mmHg,",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Proteinuria &ge;0.3 grams in a 24-hour urine specimen or protein:creatinine ratio &ge;0.3",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      or &gt;30",
"      <span class=\"nowrap\">",
"       mg/mmol",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Initial assessment for proteinuria is commonly performed by dipping a paper test strip into a fresh clean voided midstream urine specimen. Proteinuria &ge;+1 on dipstick should be confirmed by quantitative assessment (24 urine collection or protein:creatinine ratio). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23544?source=see_link\">",
"     \"Evaluation of proteinuria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mildly elevated blood pressure should be documented by at least two measurements at least four hours apart; asymptomatic outpatients with mild hypertension can be reassessed within three to seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/4\">",
"     4",
"    </a>",
"    ]. The technique for blood pressure measurement is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=see_link\">",
"     \"Blood pressure measurement in the diagnosis and management of hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with",
"    <span class=\"nowrap\">",
"     chronic/preexisting",
"    </span>",
"    hypertension who have proteinuria prior to or in early pregnancy, superimposed preeclampsia is difficult to diagnose definitively, but should be suspected when there is a significant worsening of hypertension (especially acutely) in the last half of pregnancy or development of",
"    <span class=\"nowrap\">",
"     signs/symptoms",
"    </span>",
"    associated with severe preeclampsia (",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1567356\">",
"    <span class=\"h2\">",
"     Post-diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of the post-diagnostic evaluation is to determine the severity of disease and assess maternal and fetal well-being. These factors, as well as gestational age, guide management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preeclampsia is generally classified as &lsquo;severe&rsquo; if any of the following are present in a woman with preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/3-5,74,102-104\">",
"     3-5,74,102-104",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe hypertension (systolic blood pressure &ge;160 mm Hg or diastolic blood pressure&nbsp;&ge;110 mm Hg on two occasions at least six hours apart)",
"     </li>",
"     <li>",
"      Severe proteinuria (&ge;5",
"      <span class=\"nowrap\">",
"       grams/day)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Signs/symptoms",
"      </span>",
"      of end-organ injury (",
"      <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, the history and physical examination should evaluate the patient for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe headache",
"     </li>",
"     <li>",
"      Visual abnormalities (scotomata, photophobia, blurred vision, or temporary blindness)",
"     </li>",
"     <li>",
"      Upper abdominal or epigastric pain",
"     </li>",
"     <li>",
"      Nausea, vomiting",
"     </li>",
"     <li>",
"      Oliguria",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Altered mental status",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The minimum post-diagnostic",
"    <span class=\"nowrap\">",
"     laboratory/imaging",
"    </span>",
"    evaluation should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet count",
"     </li>",
"     <li>",
"      Serum creatinine",
"     </li>",
"     <li>",
"      Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT)",
"     </li>",
"     <li>",
"      Obstetrical ultrasound (fetal weight, amniotic fluid volume)",
"     </li>",
"     <li>",
"      Fetal assessment (biophysical profile or nonstress test)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional tests that can be informative include blood smear and serum lactate dehydrogenase (LDH) and bilirubin concentrations. Microangiopathic hemolysis is suggested by elevated LDH and indirect bilirubin levels and red cell fragmentation (schistocytes or helmet cells) on peripheral blood smear (",
"    <a class=\"graphic graphic_picture graphicRef70851 graphicRef50715 \" href=\"UTD.htm?34/52/35657\">",
"     picture 2A-B",
"    </a>",
"    ). Hemoconcentration occurs in preeclampsia, but hemolysis, if present, can decrease the hematocrit to normal or anemic levels.",
"   </p>",
"   <p>",
"    Coagulation function tests (eg, prothrombin time, activated partial thromboplastin time, fibrinogen concentration) are usually normal if there is no thrombocytopenia or liver dysfunction; therefore, they are not checked routinely [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15110283\">",
"    <span class=\"h3\">",
"     Preexisting hypertension versus mild preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the reduction in blood pressure that typically occurs early in pregnancy, a woman with preexistent hypertension may be normotensive when first seen by the obstetrical provider. Later in pregnancy when her blood pressure returns to its prepregnancy baseline, she may appear to be developing mild preeclampsia if there are no documented prepregnancy blood pressure measurements.",
"   </p>",
"   <p>",
"    In this setting, a variety of factors can be helpful in establishing the likely diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypertension occurring before the 20th week is usually due to preexisting hypertension rather than to preeclampsia.",
"     </li>",
"     <li>",
"      Proteinuria is present and increases with time in preeclampsia, occasionally reaching the nephrotic range; by comparison, protein excretion is usually absent or less than 1",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in hypertensive nephrosclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6824?source=see_link\">",
"       \"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preeclampsia is more common in nulliparas than in multiparas.",
"     </li>",
"     <li>",
"      Preeclampsia is more common in older (&gt;40 years) nulliparas, although these women are also more likely to have preexisting hypertension, as are older multiparous women (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normally, plasma uric acid concentration decreases in early pregnancy and then increases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Preeclampsia is typically associated with a rise in the plasma urate level to above 5.5 to 6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (327",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/108\">",
"     108",
"    </a>",
"    ]. The plasma urate concentration tends to remain below this level in preexisting hypertension, unless the patient is taking diuretics or has superimposed preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/107\">",
"     107",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15110789\">",
"    <span class=\"h3\">",
"     Superimposed preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women with known primary (essential) hypertension and increasing blood pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria, the presence of systemic manifestations of severe preeclampsia, such as thrombocytopenia, hemolysis, increased serum levels of aminotransferases, and visual symptoms strongly suggest development of superimposed preeclampsia (",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/109\">",
"     109",
"    </a>",
"    ]. In the absence of features of severe preeclampsia, an elevated uric acid level (&ge;5.5",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    supports the diagnosis of superimposed preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/107,110\">",
"     107,110",
"    </a>",
"    ]. Reproductive age women with primary (essential) hypertension typically have no or mild proteinuria so severe proteinuria suggests development of superimposed preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Exacerbation of preexisting renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superimposed preeclampsia frequently develops in women with preexisting primary or secondary renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. However, worsening hypertension and proteinuria in a woman with preexisting renal disease may also represent an exacerbation of the underlying disease or the physiological effects of pregnancy. The ability to accurately distinguish among these possibilities is important, as management and complications are different.",
"   </p>",
"   <p>",
"    Significant clues to the diagnosis of severe preeclampsia are the presence of systemic manifestations of the disorder, such as thrombocytopenia, increased serum levels of aminotransferases, and visual symptoms (",
"    <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/109\">",
"     109",
"    </a>",
"    ]. Onset of disease in the first half of pregnancy suggests exacerbation of underlying renal disease, rather than preeclampsia.",
"   </p>",
"   <p>",
"    Laboratory evidence suggestive of exacerbation of renal disease includes the presence of findings specific for disease activity (eg, low complement levels in a patient with systemic lupus erythematosus, urinalysis consistent with a proliferative glomerular disorder [red and white cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cellular casts]). An active urine sediment is not a feature of preeclampsia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21816?source=see_link\">",
"     \"Pregnancy in women with diabetic nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1567792\">",
"    <span class=\"h3\">",
"     Antiphospholipid syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension, proteinuria, and thrombocytopenia, and other signs of end-organ dysfunction can be seen in antiphospholipid syndrome. The absence of laboratory evidence of antiphospholipid antibodies excludes this diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=see_link\">",
"     \"Diagnosis of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     AFLP, TTP, HUS, SLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <span class=\"nowrap\">",
"     preeclampsia/HELLP",
"    </span>",
"    is the most common cause of hypertension, thrombocytopenia, liver abnormalities, and renal abnormalities in pregnant women, the following conditions should be considered and excluded, if possible. Laboratory findings in these disorders are compared in the tables (",
"    <a class=\"graphic graphic_table graphicRef64296 graphicRef65674 \" href=\"UTD.htm?4/44/4814\">",
"     table 5A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute fatty liver of pregnancy (AFLP). Low grade fever can be present in AFLP, but does not occur in",
"      <span class=\"nowrap\">",
"       preeclampsia/HELLP.",
"      </span>",
"      AFLP is associated with more serious liver dysfunction: hypoglycemia and disseminated intravascular coagulation are common features, while unusual in",
"      <span class=\"nowrap\">",
"       preeclampsia/HELLP.",
"      </span>",
"      AFLP is also usually associated with more significant renal dysfunction compared to",
"      <span class=\"nowrap\">",
"       preeclampsia/HELLP.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link\">",
"       \"Acute fatty liver of pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS). Although neurologic abnormalities and acute renal failure are more prominent in TTP-HUS, this disorder may be indistinguishable from severe",
"      <span class=\"nowrap\">",
"       preeclampsia/HELLP",
"      </span>",
"      syndrome. Fever and thrombocytopenia",
"      <span class=\"nowrap\">",
"       &lt;20,000/microL",
"      </span>",
"      support a diagnosis of TTP.",
"      <span class=\"nowrap\">",
"       Preeclampsia/HELLP",
"      </span>",
"      begins to resolve within 48 hours after delivery, while HUS has a more protracted postpartum course, and patients develop severe renal failure in the postpartum period. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=see_link\">",
"       \"Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Exacerbation of systemic lupus erythematosus (SLE). Flares of SLE are likely to be associated with hypocomplementemia and increased titers of anti-DNA antibodies; by comparison, complement levels are usually, but not always, normal or increased in preeclampsia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=see_link\">",
"       \"Pregnancy in women with systemic lupus erythematosus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the future, measurement of urinary or plasma angiogenic factors (soluble fms-like tyrosine kinase, placental growth factor) may be useful in distinguishing preeclampsia from other hypertensive-proteinuric disorders, but this test is investigational and not readily available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/20/27978/abstract/113-115\">",
"     113-115",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of preeclampsia\", section on 'sFlt-1, VEGF, PIGF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/53/28498?source=see_link\">",
"       \"Patient information: Preeclampsia (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=see_link\">",
"       \"Patient information: High blood pressure and pregnancy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29410?source=see_link\">",
"       \"Patient information: HELLP syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=see_link\">",
"       \"Patient information: Preeclampsia (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The four major hypertensive disorders related to pregnancy are preeclampsia, chronic hypertension, preeclampsia superimposed upon chronic hypertension, and gestational hypertension (",
"      <a class=\"graphic graphic_table graphicRef56709 \" href=\"UTD.htm?0/37/603\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14938176\">",
"       'Definitions of pregnancy-related hypertensive disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Major risk factors for development of preeclampsia include past history of preeclampsia, nulliparity, pregestational diabetes, chronic hypertension, obesity, family history of preeclampsia, and multiple gestation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gradual development of hypertension and proteinuria in the last half of pregnancy is usually due to preeclampsia, particularly in a nullipara. These findings typically become apparent after 34 weeks of gestation and progress until delivery, but some women develop symptoms earlier in gestation, intrapartum, or postpartum. (See",
"      <a class=\"local\" href=\"#H14938198\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of preeclampsia is based on the new onset of hypertension and proteinuria after 20 weeks of gestation in a previously normotensive woman (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Systolic blood pressure &ge;140 mmHg or diastolic blood pressure &ge;90 mmHg,",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Proteinuria &ge;0.3 grams in a 24-hour urine specimen or protein:creatinine ratio &gt;30",
"      <span class=\"nowrap\">",
"       mg/mmol",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of the post-diagnostic evaluation is to determine the severity of disease and assess maternal and fetal well-being. Criteria for severe disease are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef76975 \" href=\"UTD.htm?42/60/43979\">",
"       table 2",
"      </a>",
"      ). Post-diagnostic",
"      <span class=\"nowrap\">",
"       laboratory/imaging",
"      </span>",
"      evaluation should include (see",
"      <a class=\"local\" href=\"#H1567356\">",
"       'Post-diagnostic evaluation'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Platelet count",
"     </li>",
"     <li>",
"      Serum creatinine",
"     </li>",
"     <li>",
"      Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT)",
"     </li>",
"     <li>",
"      Obstetrical ultrasound (fetal weight, amniotic fluid volume)",
"     </li>",
"     <li>",
"      Fetal assessment (biophysical profile or nonstress test)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Differential diagnosis includes exacerbation of underlying renal disease, acute fatty liver of pregnancy, thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, and exacerbation of systemic lupus erythematosus. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/1\">",
"      Sibai BM, Caritis S, Hauth J, National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. What we have learned about preeclampsia. Semin Perinatol 2003; 27:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/2\">",
"      Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol 2011; 25:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/3\">",
"      Helewa ME, Burrows RF, Smith J, et al. Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy. CMAJ 1997; 157:715.",
"     </a>",
"    </li>",
"    <li>",
"     Working group report on high blood pressure in pregnancy. National Instititutes of Health, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/5\">",
"      ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 2002; 99:159.",
"     </a>",
"    </li>",
"    <li>",
"     Dolea C and AbouZahr C. Global burden of hypertensive disorders of pregnancy in the year 2000. Evidence and Information for Policy (EIP), World Health Organization, Geneva, July 2003. file://www.who.int/healthinfo/statistics/bod_hypertensivedisordersofpregnancy.pdf (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/7\">",
"      Wallis AB, Saftlas AF, Hsia J, Atrash HK. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am J Hypertens 2008; 21:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/8\">",
"      Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/9\">",
"      Chang J, Elam-Evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/10\">",
"      Main EK. Maternal mortality: new strategies for measurement and prevention. Curr Opin Obstet Gynecol 2010; 22:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/11\">",
"      MacKAy AP, Berg CJ, Liu X, et al. Changes in pregnancy mortality ascertainment: United States, 1999-2005. Obstet Gynecol 2011; 118:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/12\">",
"      Livingston JC, Livingston LW, Ramsey R, et al. Magnesium sulfate in women with mild preeclampsia: a randomized controlled trial. Obstet Gynecol 2003; 101:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/13\">",
"      MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001; 97:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/14\">",
"      Schutte JM, Steegers EA, Schuitemaker NW, et al. Rise in maternal mortality in the Netherlands. BJOG 2010; 117:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/15\">",
"      Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ 2005; 330:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/16\">",
"      Sibai BM, el-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986; 155:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/17\">",
"      van Rijn BB, Hoeks LB, Bots ML, et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 2006; 195:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/18\">",
"      Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991; 165:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/19\">",
"      Gaugler-Senden IP, Berends AL, de Groot CJ, Steegers EA. Severe, very early onset preeclampsia: subsequent pregnancies and future parental cardiovascular health. Eur J Obstet Gynecol Reprod Biol 2008; 140:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/20\">",
"      Campbell DM, MacGillivray I, Carr-Hill R. Pre-eclampsia in second pregnancy. Br J Obstet Gynaecol 1985; 92:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/21\">",
"      Xiong X, Fraser WD, Demianczuk NN. History of abortion, preterm, term birth, and risk of preeclampsia: a population-based study. Am J Obstet Gynecol 2002; 187:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/22\">",
"      Dawson LM, Parfrey PS, Hefferton D, et al. Familial risk of preeclampsia in Newfoundland: a population-based study. J Am Soc Nephrol 2002; 13:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/23\">",
"      Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. BJOG 2004; 111:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/24\">",
"      Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol 1998; 179:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/25\">",
"      Saftlas AF, Olson DR, Franks AL, et al. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990; 163:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/26\">",
"      Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993; 341:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/27\">",
"      Meekins JW, Pijnenborg R, Hanssens M, et al. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol 1994; 101:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/28\">",
"      Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011; 31:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/29\">",
"      Trogstad L, Magnus P, Stoltenberg C. Pre-eclampsia: Risk factors and causal models. Best Pract Res Clin Obstet Gynaecol 2011; 25:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/30\">",
"      Cunningham FG, Lindheimer MD. Hypertension in pregnancy. N Engl J Med 1992; 326:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/31\">",
"      Sibai BM. Pitfalls in diagnosis and management of preeclampsia. Am J Obstet Gynecol 1988; 159:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/32\">",
"      Yancey LM, Withers E, Bakes K, Abbott J. Postpartum preeclampsia: emergency department presentation and management. J Emerg Med 2011; 40:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/33\">",
"      Matthys LA, Coppage KH, Lambers DS, et al. Delayed postpartum preeclampsia: an experience of 151 cases. Am J Obstet Gynecol 2004; 190:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/34\">",
"      Al-Safi Z, Imudia AN, Filetti LC, et al. Delayed postpartum preeclampsia and eclampsia: demographics, clinical course, and complications. Obstet Gynecol 2011; 118:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/35\">",
"      Sibai BM. Maternal and uteroplacental hemodynamics for the classification and prediction of preeclampsia. Hypertension 2008; 52:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/36\">",
"      Sibai BM, Stella CL. Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol 2009; 200:481.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/37\">",
"      Sibai BM. Magnesium sulfate prophylaxis in preeclampsia: Lessons learned from recent trials. Am J Obstet Gynecol 2004; 190:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/38\">",
"      Martin JN Jr, May WL, Magann EF, et al. Early risk assessment of severe preeclampsia: admission battery of symptoms and laboratory tests to predict likelihood of subsequent significant maternal morbidity. Am J Obstet Gynecol 1999; 180:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/39\">",
"      Hauth JC, Ewell MG, Levine RJ, et al. Pregnancy outcomes in healthy nulliparas who developed hypertension. Calcium for Preeclampsia Prevention Study Group. Obstet Gynecol 2000; 95:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/40\">",
"      von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011; 377:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/41\">",
"      Podymow T, August P. Postpartum course of gestational hypertension and preeclampsia. Hypertens Pregnancy 2010; 29:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/42\">",
"      Berks D, Steegers EA, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol 2009; 114:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/43\">",
"      Rafik Hamad R, Larsson A, Pernow J, et al. Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. J Hypertens 2009; 27:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/44\">",
"      Shahul S, Rhee J, Hacker MR, et al. Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: a 2D speckle-tracking imaging study. Circ Cardiovasc Imaging 2012; 5:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/45\">",
"      Hankins GD, Wendel GD Jr, Cunningham FG, Leveno KJ. Longitudinal evaluation of hemodynamic changes in eclampsia. Am J Obstet Gynecol 1984; 150:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/46\">",
"      Cotton DB, Lee W, Huhta JC, Dorman KF. Hemodynamic profile of severe pregnancy-induced hypertension. Am J Obstet Gynecol 1988; 158:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/47\">",
"      Phelan JP, Yurth DA. Severe preeclampsia. I. Peripartum hemodynamic observations. Am J Obstet Gynecol 1982; 144:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/48\">",
"      Clark SL, Greenspoon JS, Aldahl D, Phelan JP. Severe preeclampsia with persistent oliguria: management of hemodynamic subsets. Am J Obstet Gynecol 1986; 154:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/49\">",
"      Mabie WC, Ratts TE, Sibai BM. The central hemodynamics of severe preeclampsia. Am J Obstet Gynecol 1989; 161:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/50\">",
"      Melchiorre K, Sutherland GR, Baltabaeva A, et al. Maternal cardiac dysfunction and remodeling in women with preeclampsia at term. Hypertension 2011; 57:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/51\">",
"      Nabatian S, Quinn P, Brookfield L, Lakier J. Acute coronary syndrome and preeclampsia. Obstet Gynecol 2005; 106:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/52\">",
"      Fleming SM, O'Gorman T, Finn J, et al. Cardiac troponin I in pre-eclampsia and gestational hypertension. BJOG 2000; 107:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/53\">",
"      Joyal D, Leya F, Koh M, et al. Troponin I levels in patients with preeclampsia. Am J Med 2007; 120:819.e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/54\">",
"      Benedetti TJ, Kates R, Williams V. Hemodynamic observations in severe preeclampsia complicated by pulmonary edema. Am J Obstet Gynecol 1985; 152:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/55\">",
"      Bauer ST, Cleary KL. Cardiopulmonary complications of pre-eclampsia. Semin Perinatol 2009; 33:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/56\">",
"      Desai DK, Moodley J, Naidoo DP, Bhorat I. Cardiac abnormalities in pulmonary oedema associated with hypertensive crises in pregnancy. Br J Obstet Gynaecol 1996; 103:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/57\">",
"      Thornton CE, von Dadelszen P, Makris A, et al. Acute pulmonary oedema as a complication of hypertension during pregnancy. Hypertens Pregnancy 2011; 30:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/58\">",
"      Barton JR, O'brien JM, Bergauer NK, et al. Mild gestational hypertension remote from term: progression and outcome. Am J Obstet Gynecol 2001; 184:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/59\">",
"      Buchbinder A, Sibai BM, Caritis S, et al. Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol 2002; 186:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/60\">",
"      Moran P, Lindheimer MD, Davison JM. The renal response to preeclampsia. Semin Nephrol 2004; 24:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/61\">",
"      Moran P, Baylis PH, Lindheimer MD, Davison JM. Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 2003; 14:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/62\">",
"      Garovic VD, Wagner SJ, Turner ST, et al. Urinary podocyte excretion as a marker for preeclampsia. Am J Obstet Gynecol 2007; 196:320.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/63\">",
"      Taufield PA, Ales KL, Resnick LM, et al. Hypocalciuria in preeclampsia. N Engl J Med 1987; 316:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/64\">",
"      August P, Marcaccio B, Gertner JM, et al. Abnormal 1,25-dihydroxyvitamin D metabolism in preeclampsia. Am J Obstet Gynecol 1992; 166:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/65\">",
"      Powers RW, Bodnar LM, Ness RB, et al. Uric acid concentrations in early pregnancy among preeclamptic women with gestational hyperuricemia at delivery. Am J Obstet Gynecol 2006; 194:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/66\">",
"      Thangaratinam S, Ismail KM, Sharp S, et al. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG 2006; 113:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/67\">",
"      Cnossen JS, de Ruyter-Hanhij&auml;rvi H, van der Post JA, et al. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review. Acta Obstet Gynecol Scand 2006; 85:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/68\">",
"      Urato AC, Bond B, Craigo SD, et al. Admission uric acid levels and length of expectant management in preterm preeclampsia. J Perinatol 2012; 32:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/69\">",
"      Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol 2007; 18:2281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/70\">",
"      Henao DE, Mathieson PW, Saleem MA, et al. A novel renal perspective of preeclampsia: a look from the podocyte. Nephrol Dial Transplant 2007; 22:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/71\">",
"      Strevens H, Wide-Swensson D, Hansen A, et al. Glomerular endotheliosis in normal pregnancy and pre-eclampsia. BJOG 2003; 110:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/72\">",
"      Burrows RF, Hunter DJ, Andrew M, Kelton JG. A prospective study investigating the mechanism of thrombocytopenia in preeclampsia. Obstet Gynecol 1987; 70:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/73\">",
"      Prieto JA, Mastrobattista JM, Blanco JD. Coagulation studies in patients with marked thrombocytopenia due to severe preeclampsia. Am J Perinatol 1995; 12:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/74\">",
"      Magee LA, Helewa M, Moutquin JM, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008; 30:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/75\">",
"      Minakami H, Oka N, Sato T, et al. Preeclampsia: a microvesicular fat disease of the liver? Am J Obstet Gynecol 1988; 159:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/76\">",
"      Dani R, Mendes GS, Medeiros Jde L, et al. Study of the liver changes occurring in preeclampsia and their possible pathogenetic connection with acute fatty liver of pregnancy. Am J Gastroenterol 1996; 91:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/77\">",
"      Walters BN. Preeclamptic angina--a pathognomonic symptom of preeclampsia. Hypertens Pregnancy 2011; 30:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/78\">",
"      Swank M, Nageotte M, Hatfield T. Necrotizing pancreatitis associated with severe preeclampsia. Obstet Gynecol 2012; 120:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/79\">",
"      Shah AK, Rajamani K, Whitty JE. Eclampsia: a neurological perspective. J Neurol Sci 2008; 271:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/80\">",
"      Shah, AK, Whitty, J. Characteristics of headache in women with eclampsia. Neurology 1999; 52(Suppl 2):A285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/81\">",
"      Schultz KL, Birnbaum AD, Goldstein DA. Ocular disease in pregnancy. Curr Opin Ophthalmol 2005; 16:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/82\">",
"      Dinn RB, Harris A, Marcus PS. Ocular changes in pregnancy. Obstet Gynecol Surv 2003; 58:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/83\">",
"      Roos NM, Wiegman MJ, Jansonius NM, Zeeman GG. Visual disturbances in (pre)eclampsia. Obstet Gynecol Surv 2012; 67:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/84\">",
"      Cunningham FG, Fernandez CO, Hernandez C. Blindness associated with preeclampsia and eclampsia. Am J Obstet Gynecol 1995; 172:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/85\">",
"      CARPENTER F, KAVA HL, PLOTKIN D. The development of total blindness as a complication of pregnancy. Am J Obstet Gynecol 1953; 66:641.",
"     </a>",
"    </li>",
"    <li>",
"     Sheehan, HL, Lynch, JB. Pathology of toxaemia of pregnancy. Churchill and Livingstone, London 1973.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/87\">",
"      Richards A, Graham D, Bullock R. Clinicopathological study of neurological complications due to hypertensive disorders of pregnancy. J Neurol Neurosurg Psychiatry 1988; 51:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/88\">",
"      Drislane FW, Wang AM. Multifocal cerebral hemorrhage in eclampsia and severe pre-eclampsia. J Neurol 1997; 244:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/89\">",
"      Morriss MC, Twickler DM, Hatab MR, et al. Cerebral blood flow and cranial magnetic resonance imaging in eclampsia and severe preeclampsia. Obstet Gynecol 1997; 89:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/90\">",
"      Zeeman GG. Neurologic complications of pre-eclampsia. Semin Perinatol 2009; 33:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/91\">",
"      Zunker P, Ley-Pozo J, Louwen F, et al. Cerebral hemodynamics in pre-eclampsia/eclampsia syndrome. Ultrasound Obstet Gynecol 1995; 6:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/92\">",
"      Eastabrook G, Brown M, Sargent I. The origins and end-organ consequence of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011; 25:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/93\">",
"      Odeg&aring;rd RA, Vatten LJ, Nilsen ST, et al. Preeclampsia and fetal growth. Obstet Gynecol 2000; 96:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/94\">",
"      Xiong X, Demianczuk NN, Buekens P, Saunders LD. Association of preeclampsia with high birth weight for age. Am J Obstet Gynecol 2000; 183:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/95\">",
"      Rasmussen S, Irgens LM. Fetal growth and body proportion in preeclampsia. Obstet Gynecol 2003; 101:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/96\">",
"      Xiong X, Demianczuk NN, Saunders LD, et al. Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol 2002; 155:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/97\">",
"      Eskild A, Romundstad PR, Vatten LJ. Placental weight and birthweight: does the association differ between pregnancies with and without preeclampsia? Am J Obstet Gynecol 2009; 201:595.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/98\">",
"      Vatten LJ, Skjaerven R. Is pre-eclampsia more than one disease? BJOG 2004; 111:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/99\">",
"      Powe CE, Ecker J, Rana S, et al. Preeclampsia and the risk of large-for-gestational-age infants. Am J Obstet Gynecol 2011; 204:425.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/100\">",
"      Friedman SA, Schiff E, Kao L, Sibai BM. Neonatal outcome after preterm delivery for preeclampsia. Am J Obstet Gynecol 1995; 172:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/101\">",
"      Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994; 171:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/102\">",
"      Payne B, Magee LA, von Dadelszen P. Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011; 25:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/103\">",
"      Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010; 341:c2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/104\">",
"      Menzies J, Magee LA, Macnab YC, et al. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy 2007; 26:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/105\">",
"      Barron WM, Heckerling P, Hibbard JU, Fisher S. Reducing unnecessary coagulation testing in hypertensive disorders of pregnancy. Obstet Gynecol 1999; 94:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/106\">",
"      Lind T, Godfrey KA, Otun H, Philips PR. Changes in serum uric acid concentrations during normal pregnancy. Br J Obstet Gynaecol 1984; 91:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/107\">",
"      Lim KH, Friedman SA, Ecker JL, et al. The clinical utility of serum uric acid measurements in hypertensive diseases of pregnancy. Am J Obstet Gynecol 1998; 178:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/108\">",
"      Fadel HE, Northrop G, Misenhimer HR. Hyperuricemia in pre-eclampsia. A reappraisal. Am J Obstet Gynecol 1976; 125:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/109\">",
"      Sibai BM, Ramadan MK, Chari RS, Friedman SA. Pregnancies complicated by HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): subsequent pregnancy outcome and long-term prognosis. Am J Obstet Gynecol 1995; 172:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/110\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 125: Chronic hypertension in pregnancy. Obstet Gynecol 2012; 119:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/111\">",
"      Ihle BU, Long P, Oats J. Early onset pre-eclampsia: recognition of underlying renal disease. Br Med J (Clin Res Ed) 1987; 294:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/112\">",
"      Reiter L, Brown MA, Whitworth JA. Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension. Am J Kidney Dis 1994; 24:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/113\">",
"      Verlohren S, Stepan H, Dechend R. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci (Lond) 2012; 122:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/114\">",
"      Stepan H, Schaarschmidt W, Jank A, et al. [Use of angiogenic factors (sFlt-1/PlGF ratio) to confirm the diagnosis of preeclampsia in clinical routine: first experience]. Z Geburtshilfe Neonatol 2010; 214:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/20/27978/abstract/115\">",
"      Ohkuchi A, Hirashima C, Suzuki H, et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res 2010; 33:422.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6814 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.232-9BEAA163C5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27978=[""].join("\n");
var outline_f27_20_27978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14938176\">",
"      DEFINITIONS OF PREGNANCY-RELATED HYPERTENSIVE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1564260\">",
"      BURDEN OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14937496\">",
"      OVERVIEW OF PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14938198\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3257289\">",
"      - Atypical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H356055\">",
"      Onset &lt;20 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H356069\">",
"      Hypertension or proteinuria (not both)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10750197\">",
"      Delayed postpartum onset or exacerbation of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1566744\">",
"      Course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14938205\">",
"      Clinical features and pathophysiology by organ system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14938426\">",
"      - Cardiopulmonary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14939004\">",
"      Intravascular volume and edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14938568\">",
"      Cardiac function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14938575\">",
"      Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14938441\">",
"      - Renal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Proteinuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H942170\">",
"      Urine sediment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Renal histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hematologic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hepatic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Central nervous system and eye",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Fetus and placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1567356\">",
"      Post-diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15110283\">",
"      - Preexisting hypertension versus mild preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15110789\">",
"      - Superimposed preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Exacerbation of preexisting renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1567792\">",
"      - Antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - AFLP, TTP, HUS, SLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6814\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6814|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/2/15401\" title=\"picture 1A\">",
"      Preeclampsia light micrograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/15/28921\" title=\"picture 1B\">",
"      Preeclampsia electron micrograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/21/20831\" title=\"picture 1C\">",
"      Preeclampsia immunofluorescence microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 2A\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/13/22739\" title=\"picture 2B\">",
"      Helmet cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6814|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/31/4603\" title=\"table 1\">",
"      Criteria for preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/60/43979\" title=\"table 2\">",
"      Criteria for severe preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/37/603\" title=\"table 3\">",
"      Criteria for gestational HTN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/39/44667\" title=\"table 4\">",
"      Risk factors for preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/52/21324\" title=\"table 5A\">",
"      Diff dx preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/36/9805\" title=\"table 5B\">",
"      Differential dx lab values",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17832?source=related_link\">",
"      Abnormalities of coagulation and platelet function in preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33479?source=related_link\">",
"      Acute kidney injury (acute renal failure) in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43080?source=related_link\">",
"      Blood pressure measurement in the diagnosis and management of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6824?source=related_link\">",
"      Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27096?source=related_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29721?source=related_link\">",
"      Diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10728?source=related_link\">",
"      Doppler ultrasound of the umbilical artery for fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39801?source=related_link\">",
"      Eclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=related_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23544?source=related_link\">",
"      Evaluation of proteinuria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=related_link\">",
"      Gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/46/27370?source=related_link\">",
"      Histopathology of placental disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40888?source=related_link\">",
"      Overview of maternal mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/46/29410?source=related_link\">",
"      Patient information: HELLP syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/32/7682?source=related_link\">",
"      Patient information: High blood pressure and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/58/40867?source=related_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/53/28498?source=related_link\">",
"      Patient information: Preeclampsia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11480?source=related_link\">",
"      Prediction of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/19/21816?source=related_link\">",
"      Pregnancy in women with diabetic nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=related_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/27/36281?source=related_link\">",
"      Pregnancy risks in women with type 1 and type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42487?source=related_link\">",
"      Prepregnancy evaluation and management of women with type 1 or type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43273?source=related_link\">",
"      Reversible posterior leukoencephalopathy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=related_link\">",
"      Thrombocytopenia in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_20_27979="Pitfalls Dx seafood allergy";
var content_f27_20_27979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F65968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F65968&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic considerations when evaluating fish and shellfish allergy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Concern",
"      </td>",
"      <td class=\"subtitle1\">",
"       Implication/approach",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clinical cross-reactivity",
"      </td>",
"      <td>",
"       The rate of serologic (positive test) cross reactivity exceeds the rate of true clinical reactivity, but both are high in seafood allergy.  Therefore, caution is needed (evaluations with tests for IgE and possibly oral food challenges).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Overlap of symptoms with non-allergic seafood reactions",
"      </td>",
"      <td>",
"       Spoilage of seafood most typically results in gastrointestinal reactions that are not consistent and do not mimic allergy (differentiated by history).  However, spoilage of dark meat fish (scombroid poisoning) could result in symptoms that mimic allergy (pruritus, flushing).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reactions may vary",
"      </td>",
"      <td>",
"       Inconsistencies in reactions to fish could be attributable to manner of cooking or to which parts of the fish are eaten. Reduced digestion of fish protein is also a variable that could be altered if a patient takes antacid medication.   These points should be examined in the history and considered during allergy testing.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reactions may be attributed to seafood, but caused by other allergens",
"      </td>",
"      <td>",
"       If a reaction occurs during a meal, ingredients must be reviewed to determine other causes (spices, etc).  Other fish-related foods (caviar) or contaminants (parasites such as anisakis) could be causal",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27979=[""].join("\n");
var outline_f27_20_27979=null;
var title_f27_20_27980="Needle length IM shots";
var content_f27_20_27980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested needle length for intramuscular injection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age group, sex, weight",
"       </td>",
"       <td class=\"subtitle1\">",
"        Needle length, inches",
"       </td>",
"       <td class=\"subtitle1\">",
"        Needle length, mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Anterolateral thigh muscle injections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0 to 28 days (term or preterm)",
"       </td>",
"       <td>",
"        5/8*",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 to 12 months",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toddlers, children",
"       </td>",
"       <td>",
"        1 to 1 1/4",
"       </td>",
"       <td>",
"        25 to 32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Deltoid muscle injections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Toddlers, children",
"       </td>",
"       <td>",
"        5/8* to 1",
"       </td>",
"       <td>",
"        16* to 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"3\">",
"        Adolescents, young adults",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        &lt;60 kg (130 lbs)&nbsp;(male or female)",
"       </td>",
"       <td>",
"        5/8 to 1",
"       </td>",
"       <td>",
"        16 to 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        60 to 70 kg (130 to 152 lbs)&nbsp;(male or female)",
"       </td>",
"       <td>",
"        &nbsp;1",
"       </td>",
"       <td>",
"        &nbsp;25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        Female",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        70&nbsp;to 90 kg (152 to 200 lbs)",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 to 1 1/2",
"       </td>",
"       <td class=\"sublist_other\">",
"        25 to 38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &gt;90 kg (200 lbs)",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 1/2",
"       </td>",
"       <td class=\"sublist_other\">",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"3\">",
"        Male",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        70&nbsp;to 118 kg (152 to 260 lbs)",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 to 1 1/2",
"       </td>",
"       <td class=\"sublist_other\">",
"        25 to 38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        &gt;118 kg (260 lbs)",
"       </td>",
"       <td class=\"sublist_other\">",
"        1 1/2",
"       </td>",
"       <td class=\"sublist_other\">",
"        38",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If skin is stretched tight (subcutaneous tissues not bunched).",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27980=[""].join("\n");
var outline_f27_20_27980=null;
var title_f27_20_27981="Contents: Obstetrics calculators";
var content_f27_20_27981=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?6/40/6798\">",
"       Obstetrics, Gynecology and Women's Health",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Obstetrics calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Obstetrics calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/5/42067\">",
"           Calculator: Estimated Date of Delivery (EDD)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/15/21759\">",
"           Calculator: Estimated Date of Delivery (EDD) (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/55/9074\">",
"           Calculator: Gestational age from Estimated Date of Delivery (EDD)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-0B49DF7C58-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f27_20_27981=[""].join("\n");
var outline_f27_20_27981=null;
var title_f27_20_27982="Cholesterol level and mortality";
var content_f27_20_27982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Death from coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 422px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a direct relationship between cholesterol level and mortality among patients without coronary heart disease (CHD) and those with CHD and angina or myocardial infarction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Rosengren, A, Hagman, M, Wedel, H, et al. Eur Heart J 1997; 18:754.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27982=[""].join("\n");
var outline_f27_20_27982=null;
var title_f27_20_27983="LCH spine";
var content_f27_20_27983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Langerhans cell histiocytosis of bone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T1 weighted&nbsp;magnetic resonance imaging&nbsp;of the upper spine shows a severe flattening of the C6 vertebral body with preservation of adjacent intervertebral discs (vertebra plana deformity, short red arrow). In addition, a soft tissue mass extending into the paracervical region (short yellow arrow) with resulting spinal cord compression (long red arrow) can be identified.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_20_27983=[""].join("\n");
var outline_f27_20_27983=null;
